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ABSTRACT 
Joshua Michael Astern:  Myeloperoxidase in Vascular Disease and Autoimmunity 
 (Under the direction of Ronald J. Falk, M.D. and Gloria Preston, Ph.D.) 
 
This dissertation defines mechanisms whereby myeloperoxidase (MPO) can mediate 
vascular damage when released into the vessel, and explores the pathogenesis of an 
autoimmune disease targeting MPO.  The most abundant neutrophil granule protein, MPO 
generates powerful oxidants that contribute to innate host defense.  However, these same 
oxidants cause host injury; the release of MPO into the vessel correlates with the impairment 
of vasoregulatory processes and cellular injury.  Herein, we report that cytokeratin 1, an 
endothelial protein, mediates MPO binding and internalization.  Cytokeratin 1 also functions 
as a scaffolding protein for the vasoregulatory plasma kallikrein-kinin system. This system 
produces bradykinin, a potent inducer of endothelial nitric oxide synthesis.  Our 
investigations revealed that MPO bound and co-localized with high molecular weight 
kininogen on endothelial cells, and this interaction interfered with bradykinin cleavage by 
plasma kallikrein.  Further, MPO oxidized and inactivated both kininogen and kallikrein, 
thus preventing bradykinin release.  This work identified cytokeratin 1 as a facilitator of 
MPO-mediated responses, and provided a new paradigm by which MPO affects 
vasoregulatory processes during inflammation.  One disease characterized by excess 
intravascular neutrophil degranulation is antineutrophil cytoplasmic autoantibody (ANCA)-
mediated vasculitis.  One major ANCA specificity is for MPO (MPO-ANCA).  The origin of 
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these pathogenic autoantibodies is unknown, though our group previously published studies 
implicating proteins complementary in sequence to autoantigens as the inciting elements of 
autoimmune disease in patients with proteinase 3-specific ANCA.  In chapter 2, we 
demonstrated the presence of anti-complementary MPO antibodies in patients; this implied 
that the development of MPO-specific antibodies was a result of an anti-idiotypic response 
against the anti-complementary protein antibody, and in this way normal tolerogenic 
mechanisms were bypassed.  For this dissertation, we tested the hypothesis that 
complementary proteins could cause disease in an MPO-ANCA mouse model.  While results 
were not as we predicted, the work revealed the importance of identifying a pathogenic 
epitope.  An epitope mapping study was carried out using a mass spectrometry-based 
technique, a tool that may generate powerful data for us in the near future.  While the human 
data suggests a role for complementary proteins in MPO-ANCA disease, proving causation 
in an animal model remains an elusive goal. 
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PROLOGUE 
MYELOPEROXIDASE, THE ENZYME 
In 1941, Agner isolated an iron-containing protein with peroxidase activity from the 
purulent debris of patients with tuberculous empyema.[1] He named this protein 
verdoperoxidase due to its intensely green color, but it was renamed myeloperoxidase (MPO) 
when subsequent studies revealed that its tissue distribution was limited to myeloid cells.  
MPO is one of the principal enzymes stored in azurophilic granules of neutrophils and 
peroxidase-positive lysosomes of monocytes, and makes up 5% and 1% of each cell’s total 
protein, respectively.[2] 
The expression of the MPO gene, as well as other genes coding for granule proteins, 
is linked to the differentiation status of the myelocyte.[3] In healthy individuals, MPO gene 
expression begins at the promyelocyte stage in the bone marrow and ceases after the cells 
mature and enter the circulation.[4] MPO expression status was demonstrated in vitro using 
human promyeloid leukemic cell lines, such as HL-60 cells that express the MPO gene.  
Transcription of the MPO gene was inhibited when the cells were induced to differentiate 
using retinoic acid, dimethyl sulfoxide, or phorbol-12-myristate-13-acetate.[5, 6] 
Correlating with gene expression, MPO protein production and packaging is 
completed in the bone marrow.  The primary translation product undergoes proteolytic 
cleavage to generate an inactive apoproMPO in the endoplasmic reticulum (ER).  Subsequent 
glycosylation and insertion of a heme group in the ER yields an active, 90 kD pro-MPO 
2molecule; pro-MPO is trafficked through the trans-Golgi network and undergoes a series of 
proteolytic steps to generate a 75 kD protomer consisting of a heavy and light chain.[7-11] The 
resultant protomers dimerize, linked by a disulfide bond, and the mature enzyme is targeted 
to the azurophilic granules for storage.  Some active proMPO is constitutively secreted into 
the bone marrow and is detectable in circulation.[9, 12, 13] 
MPO plays a major role in innate host defense by participating in the oxygen-
dependent killing of invading microorganisms.  Responding to chemical signals derived from 
the infected tissue, circulating neutrophils attach to and penetrate the vascular wall, migrate 
to the site of injury, accumulate, and phagocytose the invading pathogen.  Concomitant with 
phagocytosis, the activated neutrophil undergoes a respiratory burst producing reactive 
oxygen species, including copious amounts of superoxide that is rapidly dismutated to 
hydrogen peroxide (H2O2).[14] The granules fuse to the phagosome and release their armory 
to destroy the microorganism.  Granule constituents are also secreted into the extracellular 
space to combat larger organisms that cannot be phagocytosed, as well as at sites of intense 
acute inflammation that are not induced by infectious pathogens but nevertheless have 
extensive neutrophil activation, such as sites of acute inflammation induced by autoimmune 
disease.  MPO makes up approximately 25% of azurophilic granules’ protein, and achieves 
concentrations of about 100 mg/ml in the vacuole (1mM).[15, 16] MPO utilizes H2O2 to affect 
post-translational modifications of target proteins.  MPO imparts its anti-microbicidal 
properties, in part, by catalyzing a unique reaction between hydrogen peroxide and chloride 
to create the powerful oxidant hypochlorous acid (HOCl), the main chemical component of 
household bleach (Figure i).  MPO can generate other hypohalous acids as well (using 
3bromide, iodide, and thiocyanate), but chloride is the most likely substrate at physiologic 
concentrations.[17] 
HOCl is the major oxidant produced by the neutrophil, accounting for 70% of the 
oxygen consumed during the respiratory burst.[18] HOCl is a highly reactive, and thus short-
lived, species capable of both chlorination and oxidation reactions.  HOCl can react with all 
neighboring thiol and thioether groups (methionine is readily oxidized), as well as iron-sulfur 
centers, heme groups, and unsaturated fatty acids.[19] Chloramines, the most abundant HOCl 
breakdown products, are more stable and retain some of the reactant capacity of HOCl.[20] 
There are many potential effects of HOCl-mediated alterations of bacteria including the 
interruption of the membrane electron-transport chains, a loss of microbial membrane 
transport, dissipation of adenylate energy reserves, and suppression of DNA synthesis.[21] 
Proteins altered by HOCl become more susceptible to proteolysis and more immunogenic, 
enhancing both the humoral and cytotoxic immune responses.[20] The enzymatic products of 
myeloperoxidase can also promote acute inflammation in tissue by inactivating protease 
inhibitors, such as Q-1 protease inhibitor and plasminogen activator inhibitor, thus protecting 
the function of granule-derived proteases at inflammatory foci.[22, 23] 
In addition to its use of chloride as a substrate, MPO can generate reactive nitrogen 
species through the oxidation of nitrite (NO2-), a stable end-product of nitric oxide (NO) 
metabolism (Figure i).[24] An H2O2-dependent reaction, nitrite is oxidized by MPO to form 
nitrogen dioxide (NO2.), a species which is capable of nitrating both free and protein-bound 
tyrosines.[25, 26] MPO-derived HOCl can potentially catalyze an additional reaction with 
nitrite to form nitryl chloride (NO2Cl), which is also a reactive nitrogen species.  The 
nitration of tyrosine residues is linked to the altered structure and function of proteins, though 
4evidence suggests that MPO-generated nitrating species are not a major source of oxidants in 
the phagosome and their contribution to the MPO-mediated antimicrobial system remains 
questionable.[27] However, these nitrating reactions likely occur when MPO and H2O2 are 
released into the extracellular space in vivo.[28, 29] 
MYELOPEROXIDASE IN VASCULAR DISEASE 
While promoting host defense, normal inflammatory processes cause host injury that 
is generally repaired following the resolution of the initial insult.  In severe and chronic 
inflammatory conditions, the excess release of enzymatically active MPO into the circulation 
and the production of chlorinating and nitrating species (among others) is linked to 
endothelial dysfunction and the progression of cardiac disease.[30-34] 
While exploring the effects of neutrophil granule proteins on endothelial cells in 
vitro, our group discovered that MPO was internalized into cultured cells with a resultant rise 
in intracellular oxidant production.[35] Other groups confirmed and extended these studies in 
vivo, and found that free MPO can interact with anionic endothelial cell-surface 
glycosaminoglycans.[29] MPO transcytoses through endothelial cells, independent of 
neutrophil diapedesis, and settles in the subendothelial matrix where it can remain active.  
One functional consequence of this interaction is the nitration of fibronectin, which the 
authors propose could impair vascular matrix function.  MPO is also known to bind serum 
albumin through both sequence and charge-based mechanisms.[36] The MPO-albumin 
complex can be internalized into caveoli via cell surface albumin binding protein receptors.  
In this dissertation, we describe a new, specific mechanism for MPO uptake by endothelial 
cells.  
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Figure i. Myeloperoxidase generated oxidants and their products. Shown is an 
addendum of MPO’s oxidant capacity.  MPO generates hypochlorous acid, a powerful 
and highly reactive oxidant.  Radical products of MPO catalysis (RH = reducing 
substrate; .R = oxidized radical product) promote the catalysis of nitric oxide (.NO) to 
nitrite (NO2-).  A hydrogen peroxide-dependent reaction, MPO converts nitrite to 
nitrogen dioxide (.NO2), a reactive nitrogen species.   
 
6One form of endothelial dysfunction is the lack of normal dilatory responsivity to 
appropriate stimuli, for example, because of a decrease in the bioavailablilty of nitric 
oxide.[37] MPO is now recognized as a nitric oxide oxidase, and can interfere with 
endothelial NO signaling multiple ways.  As MPO localizes at the interface between 
endothelial and smooth muscle cells, it creates small radical intermediates that catalytically 
consume NO, oxidizing it to nitrite.[24] Altering the efficiency of endothelial nitric oxide 
(eNOS), which produces NO, hypochlorous acid can chlorinate L-arginine thereby depleting 
the substrate for eNOS.[38] Additionally, HOCl can chlorinate lipoproteins, such as HDL and 
LDL.  These chlorinated lipoproteins have been localized to atherosclerotic lesions, and can 
both provoke the dissociation of eNOS from the cell membrane and destabilize eNOS 
mRNA, collectively decreasing the amount of NO produced.[39, 40] Herein, we present a new 
paradigm whereby MPO may contribute to endothelial dysfunction in inflammatory 
conditions.  
The role of MPO in endothelial dysfunction has been investigated in vivo in both 
mouse models and clinical studies.  MPO null mice presented with acute inflammatory 
stimuli had improved vascular function and increased NO availability when compared to 
wild type mice.[24] Multiple studies reveal that plasma levels of MPO inversely correlate 
with the endothelial response to NO-liberating acetylcholine in patients undergoing 
reperfusion from myocardial ischemia and as well as others with documented coronary artery 
disease[41]. Further, circulating MPO plasma levels independently predict endothelial 
dysfunction in humans.[33] Taken together, these studies support the clinical significance of 
the mechanistic link between vascular-associated MPO and NO catabolism. 
7Endothelial dysfunction is a common condition underlying hypertension, diabetes, 
aging, and atherosclerosis.  There is a growing body of laboratory and clinical evidence 
linking oxidative stress and MPO to such disorders, especially atherosclerosis.  Smooth 
muscle cells proliferate and migrate into developing atherosclerotic lesions, leading to the 
enlargement of lipid-laden plaques.  A normal role of NO production by endothelial cells is 
to suppress smooth muscle cells proliferation; this regulatory mechanism could be 
compromised by MPO’s interference with NO signaling.[42] Immunohistochemical studies 
have demonstrated the co-localization of MPO and HOCl-modified lipoproteins in 
atherosclerotic plaques.[40, 43] MPO oxidizes HDL and LDL in both atherosclerotic plaques 
and in the circulation. The lipoproteins isolated from atherosclerotic plaques and the 
circulation of patients with established coronary disease showed increased levels of 
nitrotyrosine, and chlorotyrosine modification, as compared to healthy controls.[44-47] These 
oxidized lipoproteins are preferentially removed from circulation by macrophages, leading to 
foam cell formation and the progression of atherosclerotic plaques.  The oxidation of HDL 
creates a dysfunctional molecule. HDL is referred to as the “good” cholesterol because it 
promotes cholesterol efflux from cells in the artery wall by the ATP-binding cassette 
transporter A1 (ABCA1).  When apolipoprotein A1, which accounts for 70% of total protein 
associated with HDL, is chlorinated by MPO, HDL loses its ability to remove cholesterol 
from cells.[44, 48, 49] This leads to further buildup of lipids in the artery wall, promoting 
atherogenesis.   
In addition to promoting growth of the plaque, the production of HOCl by MPO can 
also lead to plaque rupture and an acute cardiac event.  The capping of plaques through 
extracellular matrix deposition plays a key role in stabilizing atherscerotic lesions.  Matrix 
8metalloproteinases (MMP) degrade matrix proteins through their proteolytic activity and are 
under strict control by endogenous protein inhibitors, including TIMP-1, as well as reactive 
oxygen and nitrating species.  Low levels of HOCl can not only directly activate MMPs, but 
also repress TIMP-1 activity leading to matrix degradation and plaque instability.[50] HOCl 
can provoke desquamation and endothelial cell death by either apoptotic or oncotic cell-death 
pathways, potentially leading to plaque erosion and a thrombotic event.[51] 
The growing body of evidence implicating MPO in cardiovascular disease has lead to 
a number of exciting clinical studies.  A study in 2001 identified MPO as marker for 
coronary artery disease.[34] The researchers found that increased blood-MPO was 
significantly greater in patients with established coronary artery disease compared to healthy 
controls.  Two independent studies in 2003 revealed that blood levels of MPO could 
powerfully predict the incidence of major cardiac events following the initial visit of patients 
presenting with acute coronary syndrome or chest pain.[30, 52] Interestingly, both studies 
revealed that MPO predicted adverse outcome even when troponin T, a marker of myocardial 
necrosis commonly used to predict risk, did not.  The authors bring to light the importance of 
the predictive value MPO in the absence of circulating troponins, as this suggests that MPO 
release actually preceeds myocardial injury and identifes patients with unstable plaques 
before complete microvascular obstruction.   
It is becoming increasingly clear that the MPO-H2O2-Cl- system, through vascular 
neutrophil and monocyte degranulation, contributes to morbidity in several diseases.  
Increased plasma levels of MPO have been noted in inflammatory diseases such as Behcet’s 
disease, dermatitis herpetiformis, systemic inflammatory response syndrome, and ANCA-
mediated glomerulonephritis.[53-56] In addition to being a plasma marker of inflammation, 
9MPO clearly contributes to the progression of degenerative and immunologic mediated 
diseases of the kidney and is present in inflamed lung tissue.[36, 57] Because of these 
deleterious effects, it is important we understand the interaction between MPO and the 
vasculature.  Exploring the physiologic consequences of these interactions may reveal 
therapeutic targets for intervention as a means of alleviating the inflammatory burden on 
patients and retarding disease progression.    
In Chapter 1 of this dissertation, we explored the relationship between MPO and 
endothelial cells.  We found that endothelial cells internalize MPO, in part, through an 
interaction with cell-surface cytokeratin 1.  Interestingly, cytokeratin 1 was previously 
described as an endothelial surface scaffolding protein for the plasma kallikrein-kinin system.  
This system produces the vasoactive peptide bradykinin, the most potent known inducer of 
endothelial nitric oxide production.  Because MPO is recognized to interfere with nitric oxide 
signaling, we explored the interaction of MPO with the plasma kallikrein-kinin system and 
found that MPO diminished bradykinin production.  The work in Chapter 1 provides a new 
paradigm by which MPO can modulate vascular function in acute and chronic inflammatory 
conditions.   
 
MYELOPEROXIDASE, THE AUTOANTIGEN 
MPO is a target autoantigen in a humoral autoimmune disease: anti-neutrophil 
cytoplasmic autoantibody (ANCA)-mediated small vessel vasculitis.  Twenty-five years ago, 
Davies correlated the existence of anti-neutrophil antibodies in the serum of patients with 
idiopathic, segmental, crescentic, and necrotizing glomerulonephritis.[58] A couple years 
later, van der Woude and colleagues determined that antineutrophil antibodies strongly 
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correlated with disease activity in Wegener’s granulomatosis, a disease with renal pathology 
that mirrors the description provided in Davies’ report.[59] Our group’s own investigations of 
patients with similar glomerulonephritides revealed that a subset of these antineutrophil 
autantibodies were specific for MPO.[60] Soon thereafter, proteinase 3 (PR3) was identified 
as the other major target autoantigen.[61, 62] 
ANCA are now associated with three syndromes characterized by small vessel 
vasculitis:  Wegener’s granulomatosis, microscopic polyangiitis, and Churg-Strauss 
Sydrome.[63] While these syndromes all have disease features to distinguish one from 
another, the common features include the frequent presence of ANCA (of some specificity) 
and a necrotizing glomerulonephritis with a paucity of immunoglobulin deposits in the 
glomeruli.  ANCA-mediated effects are commonly observed in glomerular and alveolar 
capillaries; life-threatening injury to these organs often develops quickly but can be 
controlled by immunosuppressive treatments.[63, 64] 
The most accepted model regarding the pathogenesis of ANCA-mediated vasculitis 
suggests that ANCA activate cytokine-primed neutrophils within the micro-circulation to 
release noxious granule constituents and toxic oxygen radicals, leading to severe bystander 
effects on endothelial cells and rapid escalation of inflammation.  Our group and others have 
demonstrated that ANCA activate neutrophils in vitro, however a debate raged on as to 
whether ANCA were merely serological markers or catalysts of disease.[65-68] The 
controversy has waned recently, as animal models of MPO-ANCA glomerulonephritis and 
systemic vasculitis revealed that ANCA are in fact pathogenic, and circulating neutrophils 
are critical to induce disease.[69, 70] Additionally, two separate case reports described a 
mother with an MPO-ANCA induced microscopic polyangiitis flare during pregnancy and 
11
apparent trans-placental transfer of disease to the newborn.  Tests revealed that the newborn 
had MPO-ANCA titers at birth and marked pulmonary hemorrhage and renal 
abnormalties.[71, 72] Following therapy and clearance of the ANCA from the neonate, the 
pulmonary-renal syndrome resolved, thus adding clinical support to the pathogenic potential 
of ANCA .  This case may represent a human “model” demonstrating that MPO-ANCA are 
pathogenic.     
 
COMPLEMENTARY PROTEINS AND THE ORIGINS OF AUTOIMMUNITY 
Why do these autoantibodies develop?  The etiology of ANCA, and of all 
autoimmune diseases, remains a mystery in medical science.  Many theories exist as to the 
origins of autoimmunity, all of which have some supporting evidence, but none of which can 
fully account for all autoimmune diseases.  Such theories include: molecular mimicry 
between foreign and self antigenic determinants that results in production of antibodies that 
cross-react to self proteins, exposure of a “hidden” alloantigen that elicits an autoimmune 
response, incomplete clonal deletion of self-reactive T- or B-cells, and a genetic 
predisposition to autoimmunity.  Our group proposed and published a new theory, termed the 
Theory of Autoantigen Complementarity (Figure ii).[73] This theory proposes that the antigen 
that incites the immunologic cascade leading to autoantibody production is actually a protein 
complementary to the autoantigen.  The immune system mounts an idiotypic response 
against the complementary protein, and subsequently, anti-idiotypic antibodies are produced 
that cross-react with the autoantigen leading to disease.  The original work conducted on this 
theory was in the context of PR3-ANCA vasculitis, and it was found that patients harbored 
antibodies specific to a complementary PR3 peptide, but healthy and disease controls did not.   
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Figure ii.  Schematic of the theory of autoantigen complementarity, as 
demonstrated in PR3-ANCA disease.  1) The host is exposed to a protein 
complementary in sequence and/or structure to a known autoantigen, derived from 
either an invading microbe or the translation of an antisense transcript.  2) An 
antibody is produced in response to the complementary protein.  3) Through the 
idiotypic network, a second antibody is elicited against the first antibody, an anti-
idiotypic response.  4) Autoimmunity:  The anti-idiotypic antibody reacts with the 
autoantigen whose sequence and/or structure is complemntary to the initiating antigen.  
5) Complementary proteins have a natural affinity because the amino acid sequence, 
surface contour, and/or hydropathy of one is the opposite of the other.  Adapted from 
Pendergraft et al, Nature Medicine 2004.
Complementary protein      
(exogenous or 
endogenous)
Microbe
1
Anti-complementary 
protein B-cell
Antibodies to 
complementary protein
2
3
4
5
Autoimmune B-cell      
(anti-idiotypic B cell)
Autoantibodies              
(anti-idiotypic antibodies)
Neutrophil
Sense protein 
(autoantigen)
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Further, when mice were immunized with a complementary PR3 peptide, they not only 
developed antibodies against the complementary peptide, but also PR3-specific antibodies 
(ANCA) as the theory predicts.  These observations are in accord with Mekler’s ideas of 
complementary protein interactions, and Jerne’s Idotypic Network Theory, both of which 
remain somewhat controversial though they have been independently confirmed and 
extended by multiple investigators. 
Our work with complementary proteins came about somewhat by chance, in an 
attempt to map the pathogenic ANCA epitopes of the PR3 protein.  Small fragments of PR3 
cDNA were subcloned into a bacterial expression vector and screened for reactivity using 
patient sera.  As expected, patients reacted to polypeptides derived from the sense strand of 
PR3, but a subset were also positive for short polypeptides coded by the antisense strand of 
the gene; some cDNA had inserted into the vector in the antisense orientation and was 
translated as such.  This discovery led us to fuse the fundamental ideas of Mekler and Jerne 
into one cohesive explanation of how ANCA, and other autoimmune diseases, can sidestep 
normal tolerogenic mechanisms by exposure to complementary epitopes and subsequently 
generate autoantibodies.   
In our work, a complementary protein is defined as one translated from the antisense 
RNA of a particular gene.  This definition of complementary peptides arose from Mekler’s 
observations regarding interesting characteristics of the genetic code. He found that 
translation of a codon in a 5’3’ direction on an antisense strand yielded an amino acid that 
always has an inverted hyropathic profile compared to its sense counterpart.  Blalock and 
Smith have extended these ideas and found that the hydropathic character of any given codon 
is determined by the second base; a second base of U generally specifies hydrophobic amino 
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acids, whereas a second base A specifies hydrophilic amino acids.  Because these two bases 
are complementary, amino acid sequences derived from the antisense strand will yield 
peptides with exactly opposite hydropathic characteristics.  Though the molecular details are 
still undefined, these complementary proteins have a natural affinity for each other.  One 
proposed mechanism for interaction is attributed to the folding of the peptides based on their 
hydropathy, as the shape of each respective peptide is proposed to mirror-image one another.  
If the folding of proteins largely has to do with charged interactions (hydrophobic side chains 
tend to congregate with other hydrophobic side chains, same for polar side chains), then the 
complementary sequences (with inverted hydropathy patterns) will produce peptides with an 
inverted shape and drive their interaction.  This is the essence of Blalock’s Molecular 
Recognition Theory.  The interaction between a hydrophobic residue and its complementary 
hydrophilic correlate may seem counterintuitive, but these interactions have been shown 
experimentally to occur.[74] Brentani and Chaiken have proposed that hydrophobic 
interactions between side chains of nonpolar residues with the hydrocarbon chains supporting 
their polar partner residue could account for complementary amino acid interactions.[75, 76] 
The converse can be true as well, as hydrophilic side chains are often connected to a 
nonpolar alkyl chain that could interact with a nonpolar side chain.[77] 
Not only have researchers been able to design complementary peptides that act as 
agonists or antagonists of hormone receptors in biological assays (ie. corticotropin or growth 
hormone-releasing hormone receptors), but there is evidence that complementarity mediates 
protein-protein interactions in nature.[78, 79]  Bost et al showed that the alignment of mRNA 
sequences of interleukin-2, epidermal growth factor, and transferrin and their respective 
receptors yielded both complementary mRNA and protein sequences in the ligand binding 
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regions of these receptors.[80] Ruiz-Opazo et al screened a cDNA library with antisense 
oligonucleotide probes for both angiotensin II and vasopressin, expecting to extract clones of 
their respective receptors.[81] To their surprise, they found a novel, dual 
angiotenin/vasopressin G-protein coupled receptor; site-directed mutagenesis studies of the 
angiotensin-binding site demonstrated that sense and complementary sequences were 
responsible for the receptor-ligand interaction.  While much of the work in this field has 
focused on receptor-ligand interactions, there are also reports that complementarity may 
mediate HIV binding to CD4 receptor, peptide binding to MHC molecules, and T-cell 
receptor binding.[82-84] Importantly, and relative to our work, antibody-antigen binding may 
also be governed by sense/complementary interactions. 
As part of their early work, Blalock and colleagues showed that complementary 
peptides to peptide hormones could mimic the binding site of the hormone receptor, as they 
represent an “internal image” of the hormone.[85] They proposed that antibodies raised 
against the complementary peptides should mimic the shape of the hormone and interact with 
the hormone receptor.  This idea was successfully employed to identify an opiate receptor, as 
antibodies raised to a complementary endorphin peptide bound to the opiate receptor and 
competed for endorphin binding in a neuroblastoma cell line.[86] This technique has since 
been used to identify several receptors of peptide hormones or proteins such as luteinising 
hormone releasing hormone, angiotensin II, fibronectin, arginine vasopressin, and substance 
P.[87-92] 
If complementary peptides have complementary shapes, and the antibodies raised 
against one peptide reflect the shape of its complement, then it stands to reason that the two 
pools of antibodies raised against each individual peptide of a complementary pair would 
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also have complementary shapes, and could thus interact in an anti-idiotypic manner.  This 
idea was put to test by Smith et al, and they found that immunoglobulin raised against 
corticotropin specifically bound immunoglobulin raised against a complementary 
corticotropin peptide; the same was true for antibodies specific for -endorphin and its 
complement.[93] This work was replicated by the same group using arbitrary complementary 
peptide antigens.[94] In more recent work, Blalock and others have harnessed this system to 
create peptide vaccines that alleviate autoimmune diseases with defined pathogenic epitopes.  
Myasthenia gravis (MG) is an autoimmune disease in which patients develop autoantibodies 
against the acetycholine receoptor that lead to destruction of the neuromuscular junction and 
progressive weakness.   MG can be induced in rats by immunizing the rats with purified 
acetylcholine receptor.  Pre-immunization with a peptide complementary to the acetylcholine 
receptor induced anti-idiotypic immunity to the pathogenic antibody and alleviated disease 
symptoms, due in part to the binding and clearance of the pathogenic autoantibodies by their 
anti-idiotypic counterpart.[95] Additionally, passive transfer of the anti-idiotypic antibodies 
similarly reduced MG incidence and severity.[96] Similar studies were successful in targeting 
the T-cell mediated symptoms of multiple sclerosis (experimental autoimmune 
encephalomyelitis) and Guillain-Barre’ syndrome (experimental autoimmune neuritis).[92, 97, 
98] 
Substantiated by observations that antibodies can interact in a specific, anti-idiotypic 
manner based on complementary shapes, Blalock proposed that complementarity may form 
the biochemical basis of Niels Jerne’s Idiotypic Network Theory.[93] Jerne hypothesized and 
provided some experimental evidence that antibodies themselves can act as antigens and 
elicit anti-antibodies, or the aforementioned anti-idiotypes, directed against the 
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complementarity-determining regions (CDRs), which are the antigen-binding regions of 
immunoglobulin molecules.[99] In turn, anti-idiotypes can elitic anti-anti-idiotypes and so on.  
Under normal conditions this network is balanced, but the introduction of an antigen disrupts 
this balance and the network is induced to restore balance.  Jerne’s group demonstrated in 
multiple reports that anti-idiotypic antibodies were formed in rabbits immunized with 
immunoglobulin.[100] Taking this further, what if a person was exposed to an antigen 
complementary in sequence and/or shape to a self antigen?  The antigen would elicit 
production of an antibody; this antibody could represent the internal image of the known self-
antigen.  If Jerne’s idiotypic network is induced, an anti-idiotypic antibody would be formed 
that would in turn cross-react with the self-antigen as the anti-idiotype would mimic the 
shape of the complementary peptide.  The end result is an immune reaction driven against a 
self antigen, or autoimmunity; this is the foundation of our Theory of Autoantigen 
Complementarity.  Three of Jerne’s postulates are very important relative to this theory: 1) 
antibodies produced by B-cells can recognize foreign or self-epitopes, 2) antibody molecules 
have immunogenic idiotopes, and 3) antibody idiotypes can mimic foreign or self epitopes.[99, 
101] 
As a whole, our ideas are not entirely new.  Others have made this connection to 
autoimmune disease, though there has been relatively little direct experimental evidence that 
complementary proteins can induce autoimmune disease.  Certainly, clues were evident in 
work investigating the idiotypic network by Shechter and collegues.  They found that mice 
immunized with insulin not only made anti-insulin antibodies, but anti-idiotypes that bound 
to the insulin receptor and produced physiologic effects.[102, 103] This reactivity to the 
receptor was shown to be specific, as a single residue mutation in the insulin used for 
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immunization prevented the development of anti-receptor antibodies.  Additionally, the 
development of the antibodies was temporal, as the anti-idiotypic antibody only appeared 
when the original anti-insulin antibody was cleared.  This work suggested that the idiotypic 
network may be one way in which the immune system is fooled into skirting normal 
tolerogenic mechanisms. 
As with us, serendipitous observations led Erlanger’s group to investigate the role of 
anti-idiotypy in autoimmune disease.  They purified antibodies specific to Bis-Q, an 
acetylcholine receptor agonist, and transferred these antibodies into rabbits in an attempt to 
induce experimental MG.  These antibodies were hypothesized to mimic the acetylcholine 
receptor, thus the anti-idiotypic antibodies (anti-anti-Bis-Q) generated against them should 
cross react and bind to the acetylcholine receptor.  Four of five animals showed severe-to-
mild signs of disease.  Additionally, following immunization of mice with the Bis-Q agonist, 
they made hybridoma cell lines from splenocytes and used the rabbit anti-Bis-Q antibodies to 
screen for monoclonal antibody-secreting clones that produced anti-idiotypes (anti-anti-Bis-
Q).[104] They found multiple clones producing what they termed “auto-anti-idiotypes” that 
also cross reacted with purified acetylcholine receptor.  Further, this same monoclonal 
strategy was utilized in the setting of Grave’s disease, in which patients have anti-thyroid 
stimulating hormone (anti-TSH) antibodies that induce hyperthyroidism.  Anti-idiotypic 
clones that bound the TSH receptor were derived from animals immunized with TSH.[105] In 
line with the Theory of Autoantigen Complementarity, they found anti-idiotypic antibodies to 
one of their anti-TSH monoclonals in one Grave’s disease patient’s plasmapheresis material.   
Along these same lines, animal studies by Schoenfeld et al have demonstrated that the 
idiotypic network could be at play in autoimmune disease.  After immunizing animals with 
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an antibody specific for an autoantigen, they showed that the mice developed the correlating 
anti-idiotypic antibody.  After 4-8 months, the mice generated anti-anti-idiotypic antibodies 
that displayed the same binding characteristics to the autoantigen as the original immunizing 
antibody, and the appearance of these antibodies was associated with emergence of typical 
disease symptoms seen in systemic lupus erythematosus, anti-phospholipid syndrome, and 
Wegener’s granulomatosis.[106-109] Based on their studies, they postulated that the analogy of 
their system to human disease is the introduction of bacteria carrying a pathogenic idiotype.  
This would incite the idiotypic network, and the formation of the anti-anti-idiotype could 
take months to years, blurring the relationship of the infection to the induction of 
autoimmunity.  This is in contrast to molecular mimicry which implies a short, simple 
induction of cross-reacting autoantibodies.[109] Additionally, the idea of a bacteria carrying a 
pathogenic idiotype is not the only source of a complementary peptide, as will be discussed 
later.  However, like Erlanger’s work, the experimental evidence suggests that the idiotypic 
network may be at play in autoimmunity. 
Until only a few years ago, the data implicating complementary epitopes and the 
idiotypic network in autoimmunity remained purely theorotical and experimental.  Routsias 
et al showed, for the first time, an intact idiotypic network in humans with autoimmune 
disease.  Autoantibodies to La/SSB complexes (subsellular ribonucleoprotein particles) are 
usually found in patients with both systemic lupus erythematosus and Sjogren’s syndrome.  
This group had previously mapped the B-cell antigenic determinants of La/SSB, and 
investigated whether patients possessed anti-idiotypic antibodies by synthesizing peptides 
specific to these determinants, as well their complementary peptide counterparts.[110, 111] 
Their patients reacted to La/SSB peptides, as expected, and a subset of these patients had 
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antibodies to the complementary peptides as well; they also show that the two antibodies 
could interact in an anti-idiotypic fashion.  Moving to mouse studies, the group found that 
immunization of the animals with either peptide (sense or complementary) induced antibody 
formation first against the immunogen, and then against its complement in a temporal 
manner.[112] Further, T-cell help was required in the generation of anti-idiotypic 
antibodies.[112, 113] In their discussion, the authors propose that molecular mimicry of a 
sequence complementary to La/SSB could be the triggering factor for this autoimmune 
response: sound familiar? 
Work by Pendergraft et al in our group began with the aforementioned discovery that 
PR3-ANCA patients had antibodies to complementary PR3, and this observation led to our 
Theory of Autoantigen Complementarity.[73] In addition to demonstrating an intact idiotypic 
network in PR3-ANCA patients, this network was recapitulated in mice; immunization of 
mice with a human complementary PR3 peptide resulted in the generation of anti-PR3 
antibodies that bound human PR3 in both ELISA assays and indirect immunofluorescent 
staining of neutrophils.  Our theory, and the experimental evidence collected by Pendergraft 
supporting the theory, is an amalgamation of all of the past work discussed above, and is 
directly in line with what earlier observations in the field have predicted.  It is interesting to 
note that Routsias et al was conducting almost identical experiments in parallel with ours in a 
different disease setting, suggesting this may be a general etiology of autoimmune 
disease.[110] 
The Theory of Autoantigen Complementarity states that the inciting immunogen 
leading to autoimmune disease is a peptide or protein complementary to the autoantigen.  
One can consider two possible sources of this complementary sequence, either an 
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endogenous or an exogenous source.  It is now known that the human transcriptome contains 
several thousand antisense transcripts that may serve to regulate gene expression.[114, 115] 
There is very little evidence that these antisense transcripts can be translated.  However, there 
is precedence of such translation, as an antisense transcript-encoded self-antigen was found 
to be expressed on a human kidney tumor.[116] Consider a pathologic setting in which 
cellular dysregulation occurs and the antisense strand of an autoantigen is transcribed and 
translated; can this “new” protein now be recognized as a foreign antigen and elicit an 
immune response?  Pendergraft et al explored this possibility and found that leukocytes from 
ANCA patients indeed had such antisense transcripts.  These were termed pathological 
antisense transcripts (PATs) as they did not occur in healthy or disease controls – whether 
these transcripts were translated remains to be investigated.  As others have also predicted, 
our group explored the notion that an invading pathogen could display a mimicking epitope 
homologous to the predicted complementary sequence of the autoantigen.  To identify 
microbial homologues of complementary PR3, the predicted amino acid sequence was 
entered into the basic local alignment search tool (BLAST), which identified several 
microbes that had previously been associated with the development of PR3-ANCA and/or the 
onset and exacerbation of PR3-ANCA vasculitis.  It is worth noting at this point that the 
hydropathic profile may be as important, or even more important, than the primary amino 
acid sequence of complementary peptides.  For example, one of the best results 
demonstrating a complementary peptide interaction was obtained using a computer-generated 
complementary peptide that assigned to each residue of the target sequence an amino acid 
with an opposite hydropathy value, rather than using sequence to dictate the antisense 
RNA.[117] Additionally, the secondary structure of proteins is not altered by amino acid 
22
substitutions, provided the frequency of hydrophilic and hydrophobic amino acids in the 
sequence is maintained.[118] The implications are that the complementary protein may be 
divergent from the predicted antisense RNA sequence but still maintain an inverted 
hyropathic profile, thus expanding the potential microbial sequences that can be considered 
complementary.  
There is another similar, but different, theory regarding antigenic complementarity in 
the origins of autoimmune disease as proposed by Root-Bernstein and colleagues.[119] They 
state that the immune response leading to autoimmunity must arise from a complex of 
complementary antigens, one of which must mimic a self-determinant.  They proposed this 
was most common in immunosuppressed people with multiple concurrent, chronic infections, 
thus increasing the probability of contracting a pair of complementary antigens.  This would 
induce the simultaneous formation of anti-idiotypic antibodies, which would continue to 
perpetuate each other’s existence and cross-react with self-determinants.  Predicting the order 
of immune responses in humans is difficult.  Regardless, both theories employ similar ideas 
as to the origin of autoimmune disease.  
Evidence has been compiling over the last 30-plus years that complementary protein 
interactions can explain a growing number of antibody-antigen and antibody-antibody 
relationships.  There are well over 50 individual reports in which complementary proteins or 
peptides were utilized in biological systems (see Heal et al for a review), and the number is 
growing as these concepts enter the mainstream.[77] Multiple scientists have predicted that 
these interactions could drive a humoral or T-cell mediated autoimmune disease, and we and 
others are beginning to show this to be the case.  The major goal of the work presented in 
Chapter 2 of this dissertation was acquiring experimental animal evidence that a polypeptide 
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complementary to an autoantigen can cause disease in an animal model.  We attempted to 
expand the application of our Theory of Autoantigen Complementarity to determine whether 
it could explain the onset of MPO-ANCA vasculitis.  Studies were carried out investigating 
the presence of anti-complementary MPO antibodies in patients, thus implicating the 
relevance of complementary proteins in this disease.  We also addressed the hypothesis that 
complementary MPO could induce disease in a mouse model.     
CHAPTER 1 
Myeloperoxidase Interacts with Endothelial Cell-surface Cytokeratin 1 and Modulates 
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ABSTRACT 
During acute inflammation, functional myeloperoxidase (MPO) is released as a result 
of neutrophil degranulation, and, in some inflammatory conditions, is detectable in the 
circulation.  MPO can also be released from neutrophils and monocytes at sites of vasculitis.  
One mechanism of resulting cellular injury involves endothelial internalization of MPO, 
which causes oxidative damage and impairs endothelial signaling.  We report the discovery 
of a protein that facilitates MPO internalization, cytokeratin 1 (CK1), identified using affinity 
chromatography and mass spectrometry.  CK1 interacts with MPO in vitro, even in the 
presence of 100% human plasma, thus substantiating biological relevance.  
Immunofluorescent microscopy confirmed that MPO added to endothelial cells can co-
localize with endogenously expressed CK1.  CK1 acts as a scaffolding protein for the 
assembly of the vasoregulatory plasma kallikrein-kinin system.  Thus we explored whether 
MPO and high molecular weight kininogen (HK) reside on CK1 together or whether they 
compete for binding. The data supported cooperative binding of MPO and HK on cells such 
that MPO masked the plasma kallikrein cleavage site on HK, and MPO-generated oxidants 
caused inactivation of both HK and kallikrein.  Collectively, interactions between MPO and 
the components of the plasma kallikrein-kinin system resulted in decreased bradykinin 
production. This study identifies CK1 as a facilitator of MPO-mediated vascular responses, 
and thus reveals a new mechanism by which MPO affects vasoregulatory systems.  
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INTRODUCTION 
Cellular injury due to inflammation is caused by the release of injurious radicals and 
proteins from granule components of neutrophils and monocytes into the extracellular space.  
MPO is one of the principal enzymes stored in azurophilic granules of neutrophils and 
peroxisome-positive lysosomes of monocytes, and comprises 5% and 1% of the cells’ total 
protein, respectively.[2] MPO imparts its antimicrobial properties by converting hydrogen 
peroxide, released from neutrophils during a  respiratory burst, into hypochlorous acid, a 
powerful oxidant that readily reacts with adjacent thiol, disulfide and amino acid residues.[17]  
Increased levels of MPO are detected in serum of patients with inflammatory disease, 
suggesting that neutrophils and/or monocytes aberrantly degranulate in the vascular 
lumen.[30, 31, 34, 54, 120] “Free” MPO spilled into the vasculature interacts with endothelial 
cells and contributes to endothelial dysfunction.[24, 41, 121] Our previous explorations of this 
process indicated that MPO is internalized by endothelial cells with a resultant rise in 
intracellular oxidant radicals.[35] Others have extended these findings by demonstrating that 
MPO transcytoses through the endothelium and concentrates in the subendothelial matrix.[29] 
Internalized MPO modulates vascular signaling and vasodilatory functions by decreasing the 
bioavailability of nitric oxide via multiple mechanisms.[24, 34] For example, hypochlorous 
acid can chlorinate L-arginine thus reducing functional substrate for endothelial nitric oxide 
synthetase, and substrate radicals produced by MPO can catalytically consume nitric oxide. 
[24, 34] 
As a continuation of our previous work, our aim was to identify proteins on the 
endothelial cell surface that specifically interacted with MPO, with the goal of finding 
proteins that facilitate its internalization.  We discovered that cytokeratin 1 is an endothelial 
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binding partner for MPO.  Cytokeratin 1 (CK1) is part of a possible endothelial receptor 
complex containing urokinase-like plasminogen activator receptor (uPAR) and the receptor 
for the globular head of complement 1q protein (gC1qR).  This multiprotein receptor 
complex is a platform for assembly and activation of the vasoregulatory plasma kallikrein-
kinin system.[122, 123] Circulating high molecular weight kininogen (HK) binds to this 
complex and serves as the endothelial receptor for the zymogen prekallikrein.  An endothelial 
membrane- and matrix-associated enzyme, prolylcarboxypeptidase, activates prekallikrein, 
which then cleaves the nonapeptide bradykinin from HK.[124] Because both MPO and HK 
interact with CK1, MPO might interfere with the functionality of the kallikrein-kininogen 
system.  
The results herein provide a novel layer of interaction between MPO and endothelial 
vasoregulatory systems that could modulate vascular function and/or potentiate vascular 
injury during inflammation.  Functional studies indicate that CK1 can facilitate 
internalization of MPO and moreover, this interaction has the potential to disrupt normal 
endothelial processes.   
 
M ATERIALS AND METHODS 
Cell Culture 
Human umbilical vein endothelial cells (HUVEC) and EGM basal media with Singlequot 
supplements were purchased from Cambrex (Rockland, MD).  Cells were typically used between 
passages 5-10.  EA.hy926, an immortalized endothelial hybridoma cell line, was kindly provided by 
Cora-Jean Edgell, Ph.D. (University of North Carolina at Chapel Hill) and cultured in 
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Gibco/Invitrogen (Carlsbad, CA) Dulbecco’s Modified Eagle Medium with penicillin-streptomycin 
and 10% fetal bovine serum.  Both cell lines were grown in a 5% CO2 humidified incubator.  
EA.hy926 cells were used in addition to HUVEC in immunofluorescence colocalization studies and 
in internalization blocking experiments.  Reproducibility of the data using two different endothelial 
cell lines lends confidence in its validity and implies generality in endothelial systems. 
Antibodies 
Mouse and rabbit anti-human MPO antibodies were purchased from DAKO 
(Carpinteria, CA).  An additional mouse anti-human myeloperoxidase antibody was 
purchased from Abcam (Cambridge, MA).  Mouse anti-proteinase 3 antibodies were 
purchased from Lab Vision Neomarkers (Fremont, CA) and Research Diagostics, Inc 
(Concord, MA).  Rabbit anti-CK1 antibody was purchased from Covance Research Products 
(Berkley, CA), and the mouse pan-cytokeratin antibody (clone PCK-26) was from Sigma (St. 
Louis, MO).  Affinity purified goat anti-CK1 antibody was prepared as previously 
characterized.[125, 126] Normal total IgG of all species was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA).   Horseradish peroxidase-conjugated secondary antibodies 
were purchased from Chemicon (Temecula, CA), and Alexafluor 488- and 569-conjugated 
secondary antibodies were purchased from Invitrogen (Carlsbad, CA).  Alkaline 
phosphatase-conjugated streptavidin was purchased from Pierce (Rockford, IL).  Alkaline 
phosphatase-conjugated Affinipure F(ab’)2 fragment donkey anti-mouse IgG was from 
Jackson Immunoresearch Laboratories (West Grove, PA).  The alkaline phosphatase 
substrate kit was either from Bio-Rad Laboratories (Hercules, CA) or Pierce. 
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Purified Proteins 
MPO and catalase were purchased from Calbiochem (San Diego, CA).  Proteinase 3 
was purchased from Weislab AB (Lund, Sweden).  Recombinant CK1 (rCK131) was prepared 
as previously reported.[126] Pooled human cytokeratins and L-methionine were purchased 
from Sigma.   High molecular weight kininogen, plasma kallikrein, Factor XII (SA 27.77 
U/mg), and high molecular weight kininogen-deficient human plasma were purchased from 
Enzyme Research Laboratories (South Bend, IN).  PilB, a methionine sulfoxide reductase 
derived from Neisseria gonorrhoeae, was generously provided by Dr. Nathan Brot at Cornell 
University Joan and Sanford I. Weill Medical College.     
Immunoprecipitations of MPO and CK1 
HUVEC lysates were prepared as either whole cell or membrane fraction lysates. To 
prepare the whole cell lysate, HUVEC were washed with ice cold PBS and scraped in lysis 
buffer (25 mM HEPES, 12.5 mM MgCl2, 150 mM KCl, 0.5% NP40, 1 mM sodium 
orthovanadate, 50 mM sodium fluoride, and Roche (Almeda, CA) complete EDTA 
proteinase inhibitor cocktail at 4WC.  Glycerol was added to 10%.   Lysates were pooled and 
split evenly into 3 tubes.  Insoluble debris was centrifuged and separated from lysate.  
Membrane fraction lysate was prepared using Pierce’s MEM-PER isolation kit as instructed 
with the addition of sodium fluoride, sodium orthovanadate, and the Roche protease inhibitor 
cocktail.  The pooled membrane fraction was dialyzed in PBS + 1% NP40 overnight for 3 
nights, changing the dialysate each night.  Glycerol was added to 10% and the pooled lysate 
split evenly into 3 tubes.  Protein A/G beads (Pierce) and normal mouse IgG were added to 
each tube for 1 hr at 4WC and then centrifuged to pre-clear the lysate.  Ten micrograms of 
purified proteinase 3 or MPO was added to the lysates for 5 hours at 4WC, and mouse anti-
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MPO or anti-PR3 antibodies were added to the appropriate tubes overnight.  Protein A/G 
beads were added to the tubes for 1 hr at 4WC.  The beads were washed with lysis buffer and 
PBS and any protein complexes were eluted from the beads directly in Laemmli buffer.  The 
samples were subjected to SDS-PAGE and then stained with Coomassie Brilliant Blue R-
250.  Unique bands in the MPO immunoprecipitation lane were excised and analyzed by 
MALDI-TOF at the University of North Carolina’s Proteomics Core Facility using methods 
published by Parker et al.[127] 
Mouse anti-MPO antibody (100 µg) was immobilized on Pierce’s AminoLink Plus 
Coupling Gel as instructed.  HUVEC were washed with ice cold HBSS and scraped at 4WC
into lysis buffer (formulation above) containing 0.5% Triton X-100 and 10% glycerol.  The 
lysate was sheared with a 22g needle and the insoluble debris centrifuged and separated.  The 
lysate was split into 2 tubes, one of which received 2.5 µg purified MPO.  The tubes were 
rocked at 4WC for 3 hours after which immobilized mouse anti-MPO was added to the tubes 
overnight.  The gel-containing lysates were spun and washed in Pierce’s Handee Cup spin 
columns with 10 column volumes of lysis buffer and eluted using the AminoLink plus kit.  
Laemmli buffer was added to each elution fraction and the fractions were subjected to SDS-
PAGE and western blot analysis.   
Two micrograms of purified MPO was mixed with either 2 µg recombinant CK1, 2 
µg recombinant control protein, or nothing in IP buffer (25mM HEPES, 12.5 mM MgCl2,
150 mM KCl, 0.5% NP40, 10% Glycerol) overnight at 4WC with constant mixing.  Four 
micrograms of either mouse anti-MPO or mouse anti-pan CK antibody was added to the mix, 
as well as antibody alone in IP buffer, and allowed to mix overnight at 4WC.  Protein A/G 
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beads (Pierce) were added for 1 hour, washed, and protein complexes were eluted directly in 
Laemmli buffer.  Elutions were subject to SDS-PAGE and western blot analysis.    
ELISAs Demonstrating MPO Binding to CK1 and HK 
ELISA plates were coated with 5 µg/ml of either rabbit anti-CK1 or normal rabbit 
IgG overnight at 4WC.  Wells were blocked with a 0.2% fish gelatin buffer (150 mM NaCl, 50 
mM Tris base, 0.05% Tween 20, 0.2% fish gelatin, 0.02% sodium azide, pH 7.6) for 4 hours 
at room temperature, and all subsequent steps were carried out in this blocking solution.  
CK1 was captured overnight at 4WC from a mix of solubilized human keratins (10 µg/ml) 
derived from human epidermis.  Purified MPO was presented to the captured CK1 at 5 µg/ml 
at room temp for 4.5 hours.  The wells were exposed to mouse anti-MPO antibody at a 1:100 
dilution and each of three sera from patients with MPO-specific anti-neutrophil cytoplasmic 
autoantibodies (MPO-ANCA) diluted at 1:100 in duplicate overnight at 4WC.  The CK1-MPO 
complexes were detected by alkaline phosphatase-conjugated secondary antibody incubation 
for 1 hour at room temperature followed by the addition of substrate.  Plates were read at 405 
nm after 1 hour using a VERSAmax plate reader (Molecular Devices, Sunnyvale, CA).  
ELISA plates were coated with either rabbit anti-CK1 antibody or normal rabbit IgG 
at 5 µg/ml overnight at 4WC.  The wells were blocked in a 1% fish gelatin buffer for 4 hours at 
room temperature and then exposed to a 10 µg/ml solution of solubilized human keratins in 
blocking buffer overnight at 4WC to capture CK1.  Plasma was obtained from healthy subjects 
in Becton Dickinson Vacutainer tubes K3 EDTA 12mg (purple top) (Franklin Lakes, New 
Jersey).  Solutions of 0, 25, 50, 75, and 100% plasma were prepared with or without the 
addition of 5 µg/ml MPO.  The plasma solutions were prepared using 1% fish gelatin buffer 
that was drawn into the Vacutainer tubes in order to keep the EDTA concentration constant 
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throughout this stage of the experiment.  The plasma solutions were placed in the wells for 4 
hours at room temperature.  The captured MPO was labeled with the DAKO mouse anti-
MPO antibody at a 1:100 dilution at 4WC overnight.  The next day, secondary antibody was 
applied for 1 hour at room temperature followed by substrate.  The plates were read at 405 
nM 3 hours after the addition of substrate.    
ELISA plates were coated with either rabbit or mouse anti-MPO antibody, normal 
rabbit or mouse IgG, at 5 µg/ml overnight at 4WC.   The wells were blocked with 0.2% fish 
gelatin buffer for 1 hour at room temperature, and all subsequent steps were carried out in the 
blocking buffer.  MPO was captured at 5 µg/ml for 1 hour at room temperature.  Wells were 
washed thoroughly and 2 µg/ml biotinylated HK was added with or without a 75-fold excess 
of unlabeled HK in duplicate.  Unlabeled HK only was also added to wells in duplicate.  
After 1 hour at room temperature, the wells were washed and alkaline phosphatase-
conjugated streptavidin was added for an additional hour.  Following addition of substrate for 
1 hour, the plate was read at 405 nm.  Similar experiments were conducted using ELISA 
plates directly coated with either MPO or BSA. 
ELISA plates were coated with either rabbit anti-MPO antibody or normal rabbit IgG 
(5 µg/ml) overnight at 4WC.  The wells were blocked with 1% fish gelatin buffer for 2 hours at 
room temperature.  HK-deficient plasma was replenished with a physiologic concentration 
(80 µg/ml) of biotinylated high molecular weight kininogen (bHK).  The HK-deficient 
plasma was added to the wells with or without bHK overnight at 4WC.  Following thorough 
washing, alkaline phosphatase-conjugated streptavidin was added to the wells for 1 hour at 
room temperature.  Subsequently, substrate was applied and the plate was placed at 4WC
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overnight.  Spectrophotometer readings were taken at 405 nM after resting the plates at room 
temperature for 6 hours. 
Immunofluorescent Co-localization of MPO and CK1 
EA.hy926 cells were plated on glass coverslips, grown to approximately 90% 
confluence, washed, and treated with MPO (10 µg/mL) for 10 minutes in serum-free DMEM.  
The cells were washed in PBS, fixed in 4% paraformaldehyde, and permeabilized with 
acetone.  Goat serum was used as a block (at 10% in TBS with 0.05% Triton-X100) and 
antibody dilution buffer (at 1% in TBS with 0.05% Triton-X100), and the cells were labeled 
with rabbit anti-CK1 and mouse anti-MPO antibodies.  Alexafluor-conjugated secondary 
antibodies were used for detection: the Alexafluor 488 was goat anti-rabbit, and the 
Alexafluor 568 was goat anti-mouse.  The coverslips were mounted on slides with Antifade 
and analyzed using a Zeiss LSM5 Pascal Confocal Laser Scanning Microscope with the 
accompanying software suite. 
HUVEC were plated to approximately 90% confluence (140,000 cells per well)  and 
allowed to attach overnight to 0.1% gelatin-coated glass cover slips in 12 well culture dishes.  
Cells were washed twice with pre-warmed, phenol red-free EGM basal media with or 
without 2% fetal bovine serum, and MPO was added at 15 µg/mL for 12 minutes at 37WC.  
Cells were then placed on ice and washed in cold PBS, and then fixed in cold 2% 
paraformaldehyde for 45 minutes on ice.  The wells were then washed and the cells were 
then permeabilized with ice cold 1:1 methanol:acetic acid on ice for 10 minutes.  Goat serum 
was used as the blocking agent (at 10% in TBS with 0.05 % Triton-X100) and the antibody 
dilution buffer (at 1% in TBS with 0.05% Triton-X100).  The coverslips were blocked for 1 
hour at room temperature.  The cells were then labeled with the Abcam mouse anti-MPO 
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antibody (1:250 dilution) for 1 hour at room temperature, followed by rabbit anti-CK1 (1:80 
dilution) in the same conditions.  Alexafluor-conjugated secondary antibodies were used for 
detection: the Alexafluor 488 was goat anti-rabbit, and the Alexafluor 568 was goat anti-
mouse.  The secondaries were prepared at a 1:500 dilution and applied simultaneously.  The 
coverslips were mounted on slides with antifade and analyzed using a Zeiss LSM5 Pascal 
Confocal Laser Scanning Microscope with the accompanying software suite. 
Antibody Blocking Experiments 
EA.hy926 cells grown in 12-well culture dishes, or HUVEC grown in 6-well dishes 
were washed with serum-free, phenol red-free DMEM.  Cells were pretreated in the serum-
free media with blocking antibodies.  One experiment used a blocking mix consisting of 
16.67 µg/ml goat-anti CK1 (which blocks HK binding to endothelial cells) and a 50-fold 
molar excess of Factor XII (which also binds CK1) for 45 min at 37WC.[125] Other 
experiments used the pan-cytokeratin antibody or normal mouse IgG at 16.67 µg/ml for 45 
min at 37WC.  MPO (0.5-2 µg/ml) was added subsequently to the cells in the presence of the 
blocking antibodies for 10 minutes.  The cells were washed with the serum-free media and 
trypsinized.  When the cells released from the plate, either trypsin neutralizing solution 
(Cambrex) or serum-containing medium was added and the cells were collected.  The cells 
were processed using Caltag Laboratories Fix and Perm Kit (Invitrogen) and stained for 
MPO using the rabbit anti-MPO antibody in conjunction with an Alexafluor 488 chicken 
anti-rabbit secondary antibody.  The stained cells were analyzed using a FACScan flow 
cytometer linked to a CellQuest software system (Becton-Dickinson Immunocytometry 
Systems, San Jose, CA). 
35
HK Binding Studies on HUVEC 
HUVEC were plated to confluence in EGM basal media (without the Singlequot 
supplement) in 96-well tissue culture wells that were pre-coated with a 1% gelatin solution.  
Eighteen to 24 hours after plating, the cells were washed with a HEPES-carbonate buffer 
(154 mM NaCl, 5.6 mM KCl, 3.4 mM NaHCO3, 5.5 mM Dextrose, 5 mM HEPES, 2 mM 
CaCl2, 1 mM MgCl2, 0.1% gelatin, pH 7.4) and biotinylated HK was added to the cells at 20 
nM in HEPES-carbonate buffer either alone, or in the presence of a 50-fold molar excess of 
unlabeled HK or MPO for 30 minutes at 37WC.  Unbound proteins were washed away and the 
cells were treated with alkaline phosphatase-conjugated streptavidin at room temperature for 
1 hour.  The cells were washed and the substrate was applied and absorbance read at 405 nM 
after 1 hour at room temperature. 
Immunofluorescent Co-localization of MPO and HK on Endothelial Cells 
HUVEC were grown to 80% confluence on 0.1% gelatin-coated glass coverslips.  
Biotinylated HK (50 nM) was pre-mixed with a 5-fold molar excess of MPO in EGM basal 
medium.  The cells were gently washed with the EGM basal medium and the protein mix 
added for 30 minutes at 37°C.  Control groups included each protein added individually or no 
protein.  The cells were placed on ice and washed thoroughly in cold PBS and then fixed in 
1.5% paraformaldehyde for 40 minutes at room temperature.  Some coverslips were dipped 
in acetone to permeabilize the cells.  The coverslips were blocked in 10% chicken serum for 
45 minutes.  Subsequent steps were carried out in 1% chicken serum for 1 hour at room 
temperature in the order listed with thorough PBS washes in between each step: alexafluor 
488-conjugated streptavidin diluted 1:500, rabbit anti-MPO at a 1:2500 dilution, and 
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alexafluor 569-chicken anti-rabbit secondary antibody diluted 1:1500.  The coverslips were 
then mounted in Antifade medium. 
ELISAs Measuring the Effects of MPO on Bradykinin Production 
To quantitate bradykinin released in the presence of MPO, HK (50 nM) was 
incubated with 5 nM, 50 nM, or 500 nM MPO in PBS for 20 minutes at room temp in 
microcentrifuge tubes.  Kallikrein (50 nM) was added to the mix for 20 minutes at room 
temp, and the samples were frozen at -80WC for future analysis.  Samples were thawed and 
analyzed for bradykinin release using Dainippon Pharmaceuticals MARKIT-M Bradykinin 
ELISA kit (Osaka, Japan).  Our experimental samples were handled for analysis per the 
manufacturer’s instructions specific to urine specimens.  Amount of reagents added was 
adjusted to accommodate smaller volumes.  
To measure the effect of the MPO-H2O2-Cl- system activity on bradykinin 
production, HK (50 nM) was incubated with MPO (10, 50, or 250 nM) and 0.45 µM H2O2 in 
PBS in the presence or absence of catalase (10-fold molar excess to MPO) for 20 minutes at 
room temperature in microcentrifuge tubes.  L-methionine (100 µM) was added to the mix 
for 20 minutes to quench HOCl activity.  Kallikrein (50 nM) was then added for 20 minutes 
at room temperature and the samples were frozen at -80WC for future analysis.  Samples were 
thawed and analyzed for bradykinin release using the aforementioned bradykinin ELISA kit.   
To determine the direct effects of HOCl on bradykinin production, HK (50 nM) was 
pre-treated with increasing concentrations of HOCl in PBS at room temp for 20 minutes in 
microcentrifuge tubes.  A 20-fold excess of L-methionine (compared to HOCl concentration) 
was added to the mix for an additional 20 minutes.  Subsequently, kallikrein was added to 50 
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nM for 20 minutes at room temperature and the samples were frozen at -80WC for further 
analysis.  Bradykinin release was measured in the samples using the bradykinin ELISA kit.  
The unknown values were determined using a 7-point standard curve with an R-
squared value of 0.95  
Kallikrein Protease Activity 
Kallikrein (50 nM) was treated with HOCl or HOCl that was pre-incubated with a 20-
fold excess of L-methionine (to quench oxidative properties) at varying concentrations in 
microcentrifuge tubes for 15 minutes.  Subsequently, L-methionine was added to those tubes 
that received non-quenched HOCl.  Samples were transferred to a 96-well plate and 
Chromogenix S-2303 plasma kallikrein-specific chromogenic substrate (Diapharma, 
Westchester, OH) was added, mixed, and OD 405 nM was read after 30 minutes of rocking 
at room temperature.  Values were adjusted by subtracting background OD values of HOCl + 
L-methionine without kallikrein.    
Methionine Sulfoxide Reductase Assay 
HK (50 nM) was pre-treated with 25 µM HOCl in PBS for 20 minutes at room 
temperature, and unreacted HOCl was quenched with 500 µM L-methionine (a 20-fold molar 
excess) for an additional 20 minutes.  PilB (50 nM) was added  to the reaction mix in the 
presence of 15 mM dithiothreitol and 30 mM Tris-HCl (ph 7.4) for 1.5 hours at 37WC.  After 
cooling the tubes to room temperature, plasma kallikrein was added to the reaction at 50 nM 
for 25 minutes, and kallikrein activity was stopped with 0.5 µM Diisopropylfluorophosphate 
(DFP).  The samples were deproteinized using reagents provided with the Dainippon 
MARKIT-M bradykinin ELISA kit, and analyzed for bradykinin release using Bachem 
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Peninsula Laboratory’s (San Carlos, CA) Bradykinin EIA kit as per manufacturer’s 
instructions. 
 
RESULTS 
Identification of CK1 and Ck9 as Endothelial MPO-binding Proteins 
To identify endothelial cell surface proteins that bind MPO, purified MPO was 
incubated with HUVEC membrane lysates, and subsequent complexes were immunopurified 
using an anti-MPO antibody.  For comparison, proteinase 3, also a cationic neutrophil 
granule protein, was added to an aliquot of endothelial lysates and analyzed in parallel for 
binding partners.  Two proteins were identified that specifically bound MPO and not 
proteinase 3 under these conditions (Figure 1.1a).  MALDI-TOF analysis determined these to 
be cytokeratins 1 (67 kD) and 9 (62kD) (Figure 1.1b).   
CK1 was verified to physically bind MPO, using an anti-MPO affinity column to 
capture CK1 in complex with MPO in the context of HUVEC protein lysates.  Western blot 
analysis showed CK1 specifically eluted with MPO (Figure 1.1c). Mixing of purified MPO 
and CK1 further confirmed the specificity of this interaction (Figure 1.1d).  MPO specifically 
bound CK1 while a negative-control recombinant protein did not.  
We next examined whether the interaction of MPO and CK1 was limited to native 
human MPO, and moreover, whether the complex was detectable using human anti-MPO 
antibodies from patients with MPO-specific autoantibodies.[60] Sandwich ELISAs 
demonstrated that CK1 complexed with human native MPO, recombinant human MPO, and 
native mouse MPO.  MPO was detected only when an anti-CK1 antibody was present to 
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capture CK1 as compared to when a normal rabbit IgG was used as the capture antibody 
(Figure 1.1e).  The mouse anti-human MPO antibody reacted with only the native MPO 
protein.   
MPO interacts with several blood proteins such as ceruloplasmin (its natural 
inhibitor), albumin, and the lipoprotein apo-A1.[36, 128, 129] The above studies were carried out 
in total cell lysates or in serum-free buffer to test specificity.  We asked if the MPO-CK1 
interaction was influenced by the presence of plasma proteins, as found in an in vivo 
environment.  In a competition assay, purified MPO binding to immobilized CK1 was 
slightly competed away by addition of plasma from volunteer 1 and saturated at 25% plasma 
(Figure 1.1f).  This effect was more pronounced in volunteer 2, but saturated at 50%.  In 
parallel, plasma was added to immobilized CK1 without exogenously added MPO to 
determine if circulating plasma MPO would bind.  Free MPO in plasma bound CK1 and, 
interestingly, binding was maximal at the concentration coinciding with the saturation point 
with excess added MPO, indicating all available CK1 was complexed.   
To test this interaction at the cellular level, cells expressing surface CK1 were treated 
with MPO in the absence or presence of plasma and analyzed for the ability of these proteins 
to colocalize. By immunofluorescence microscopy, MPO colocalized with CK1 expressed on 
EA.hy926 cells and on HUVEC (Figure 1.2).  Widespread colocalization was noted in 
HUVEC on the cell surface and intracellularly in both the absence and presence of serum 
(2%).  Based on this data, MPO binding to CK1 is highly likely to occur in vessels.    
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Figure 1.1.  Cytokeratins 1 and 9 Specifically Bind MPO. Note: Figure legend 
on following page 
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Figure 1.1.  Cytokeratins 1 and 9 Specifically Bind MPO. a) Coomassie stained 
gel of immunopurified MPO or proteinase 3 (PR3) complexes resolved by SDS-
PAGE. Mass spectrometry analysis of the unique bands in the MPO-spiked membrane 
fraction identified cytokeratins 1 and 9.  The spectra are shown in b) The tryptic 
peptides are numbered and displayed  with the corresponding sequences.  c) Western 
blot analysis verified that CK1 binds to MPO. HUVEC whole cell lysates were 
incubated with purified MPO, and passed over a monoclonal MPO-specific antibody 
immobilized on Aminolink Plus coupling gel. The proteins eluted from the beads were 
subjected to SDS-PAGE and western blot analysis using cytokeratin 1-specific 
antibody.  E1, E2 and E3 are sequential elution fractions from the beads. d) In vitro 
mixing of purified proteins resulted in the binding of MPO to CK1, but not but not to a 
control recombinant protein (BMP7). Western blot analysis (IB) of immunopurified 
complexes (IP) indicated that an anti-CK1 antibody (Ab) immunoprecipitated MPO, 
but only when complexed with CK1.  MPO does not bind the control recombinant 
protein demonstrating the specificity of the MPO-CK1 interaction. e) Sandwich 
ELISAs: the different shapes represent the antibody used to detect MPO binding.  
Solid black indicates the ELISA well was coated with a CK1 antibody, and open shape 
indicates the well was coated with normal IgG.  Antibody-captured CK1 was 
incubated with purified MPO, recombinant MPO, or purified mouse MPO.  Results 
show that purified MPO was detected by the monoclonal MPO antibody, but this 
antibody did not react with recombinant MPO or mouse MPO. Anti-MPO antibodies 
from three patients with ANCA disease (MPO-ANCA) recognized the CK1-MPO 
complex with all three forms of MPO protein. f) CK1 captures MPO directly from 
human plasma.  ELISA wells were coated with either anti-CK1 antibody or normal 
IgG.  CK1 was then captured and incubated with or without MPO in increasing 
amounts of plasma drawn from two healthy volunteers (V1 and V2). 
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Figure 1.2. MPO and CK1 colocalize in living cells. a) EA.hy926 cells were 
incubated with MPO in serum-free medium. MPO was detected with the Dako mouse 
anti-MPO antibody, and CK1 was detected using a polycloal anti-CK1 antibody.  The 
yellow foci in the merged image indicate areas of colocalized CK1 and MPO.  b and 
c) HUVEC were also exposed to MPO in serum free (b) or serum-containing (c)
medium.  MPO was labeled in this experiment with a mouse-MPO antibody from 
Abcam.  CK1 was labeled with the same polyclonal antibody used in a. Widespread 
colocalization was noted in both conditions.  d) Negative control for the CK1 label on 
HUVEC (anti-rabbit secondary antibody only).  e)  Negative control for the MPO 
label on HUVEC (cells not treated with MPO but exposed to the anti-MPO antibody 
and its corresponding secondary antibody).  All images were produced at 60X 
magnification. 
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Internalization of MPO by Endothelial Cells is Blocked by Interfering with the MPO-CK1 
Interaction 
 
To test whether CK1 participates in the uptake of MPO, we performed a blocking 
experiment using anti-CK1 antibodies.  Following antibody treatment, cells were analyzed 
for uptake of added MPO by flow cytometry.  Experimental design included a trypsinization 
step to remove residual MPO not internalized by the cells.  MPO uptake was reduced in the 
presence of anti-CK1 antibodies but not IgG controls (Figure 1.3).  Blocking of MPO 
internalization was concentration dependent, i.e. saturation of the system with MPO 
overwhelmed the antibody blocking effects (Figure 1.3a).  A blocking mix consisting of a 
polyclonal goat anti-CK1 antibody and FXII reduced the percentage of MPO-positive 
EA.hy926 cells from 42.1% to 6.1% when the cells were treated with 2 µg/ml MPO, but did 
not block when treated with 5 µg/ml MPO. Similar results were obtained when a monoclonal 
antibody specific for type II cytokeratins was used as a blocking antibody on HUVEC.  Pre-
treatment with this antibody resulted in more than a 50% decrease in the number of MPO-
positive cells (Figure 1.3b).  This monoclonal was used to block CK1 on EA.hy926 cells, 
however, in this experiment normal mouse IgG was tested to assure that the mouse IgG, in 
general, was not responsible for blocking MPO.  The CK antibody decreased the number of 
MPO-positive cells from 33% (with the normal mouse IgG) to 12.7% (Figure 1.3c).   
MPO Directly interacts with HK 
To investigate potential effects of MPO binding to CK1 on vascular processes, we 
asked if MPO would compete with HK for binding to CK1, since HK is known to also bind  
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Figure 1.3.  Internalization of MPO by Endothelial Cells is Reduced by Blocking 
the MPO and CK1 Interaction. Experiments are flow cytometry analyses of 
endothelial cells labeled with a polyclonal anti-MPO antibody.  a) EA.hy926 cells 
were pre-treated with a CK1-blocking mix consisting of factor XII (FXII) and a goat 
anti-CK1 antibody (CK Ab) raised against a kininogen binding site of CK1.  Cells 
were then exposed to 2 or 5 Zg/ml MPO for 10 minutes.  b) HUVEC were pre-treated 
with a pan-CK (pCK Ab) antibody and then 2 Zg/ml MPO was added for 10 minutes.  
c) EA.hy926 cells were pre-treated with either a pan-CK (pCK Ab) antibody or 
normal mouse IgG before 0.5 Zg/ml MPO was added for 10 minutes. 
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Figure 1.4. MPO Enhances Kininogen Binding to Endothelial Cells and 
the Proteins Co-localize on the Endothelial Cell Surface and Intracellularly. a)
MPO enhances kininogen binding.  HUVEC were treated with biotinylated high 
molecular weight kininogen (bHK) either alone, or in the presence of a 50-fold molar 
excess of unlabeled high molecular weight kininogen (uHK) or MPO for 30 minutes at 
37WC.  Bound bHK was detected using alkaline phosphatase-conjugated streptavidin.  
Unlabeled HK competed with bHK binding resulting in 50% less bHK protein bound.  
MPO enhanced bHK binding by 5.35-fold. b-e) MPO and kininogen colocalize in/on 
endothelial cells.  HUVEC were either treated with bHK and purified MPO (b-d) or
protein-free medium (e).  The cells were labeled using both alexafluor 488-conjugated 
streptavidin (b) and an anti-MPO antibody with corresponding alexafluor 568 
secondary antibody (c).  d) The merged image of B and C showing a high degree of 
colocalization between MPO and bHK.  The merged image of cells that were treated 
with protein-free medium is shown in e.  All images were produced at 60X 
magnification. 
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CK1.[130]  Rather than compete for CK1 binding, a more than 5-fold increase in binding of 
biotinylated HK was observed in the presence of MPO (50-fold excess), while the controls 
using a 50-fold excess of unlabeled HK blocked biotinylated HK binding by 40% (Figure 
1.4a).  Moreover, by immunofluorescence microscopy, MPO and HK were found to 
colocalize at the surface membrane and in the cytoplasm of endothelial cells (Figure 1.4b).  
We next asked if enhanced binding could be due to a direct interaction between HK and 
MPO.  Data from a direct ELISA (Figure 1.5a) and from a capture ELISA (Figure 1.5b and 
c) verify that MPO and HK have the capability to physically interact. Importantly, we also 
showed that immobilized MPO bound kininogen from plasma (1.Figure 5d), thus 
demonstrating that this interaction is favored in a physiologic matrix.      
MPO Interferes with the Plasma-Kallikrein Kinin System 
To further explore MPO-mediated effects on the plasma kallikrein-kinin pathway, we 
tested whether MPO affected bradykinin production.  We hypothesized that MPO binding to 
HK would interfere with its cleavage by kallikrein to produce bradykinin.  Bradykinin 
production from HK by plasma kallikrein was monitored in an in vitro system with and 
without MPO.  The results indicate that a 10-fold molar excess of MPO (500 nM) to HK 
reduced bradykinin production by 30% compared to equimolar concentrations (50 nM) 
(Figure 1.6a).  The data indicate that MPO’s binding to HK physically hinders the 
accessibility of the kallikrein cleavage site on HK.  We next asked if MPO’s peroxidase 
function would influence bradykinin production. The data indicate that when hydrogen 
peroxide (H2O2), the substrate of MPO, is present, inhibition of bradykinin production is 
enhanced showing a significant reduction at 250 nM (Figure 1.6b) versus 500 nM MPO 
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without H2O2. Supporting that the conversion of H2O2 and Cl- to hypochlorous acid by MPO 
was involved, the addition of catalase, an H2O2 scavenger, reversed this effect (Figure 1.6c).   
Effects of HOCl of Kallikrein and HK  
HOCl, an antimicrobial oxidant produced by MPO, has long been implicated in the 
injury caused by inflammation, as it readily reacts with - and alters - proteins and their 
functions.[17] Thus, proteins in close proximity of MPO could be affected by MPO-produced 
HOCl.  We first evaluated the effects of HOCl on the protease activity of plasma kallikrein, 
using a colorimetric activity assay.  Kallikrein activity was inhibited 50% at an 80-fold molar 
excess of HOCl to kallikrein and completely inhibited at a 200-fold excess (Figure 1.7a).  A 
20-fold molar excess of L-methionine to HOCl quenched its oxidant activity,[17] as thiols and 
thioether groups of methionine are the most reactive substrates for HOCl oxidation.   
Kininogens oxidized by chloramines (stable breakdown products of HOCl) cannot 
bind prekallikrein or be cleaved by kallikrein, an effect attributed to a modification of the 
critical Met-361 residue adjacent to the internal kinin sequence in kininogen to methionine 
sulfoxide.[131, 132] HOCl can mediate this same methionine-specific chemistry, thus we 
hypothesized HOCl would oxidize HK preventing bradykinin release by kallikrein.[50, 133] 
Addition of HOCl to HK inhibits bradykinin production in a dose-dependent manner (Figure 
1.7b). The addition of PilB, a methionine sulfoxide reductase, reversed the decrease in 
bradykinin production and verified that a HOCl-oxidized methionine was responsible for this 
reduction. 
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Figure 1.5. MPO Binds Kininogen. a) Direct ELISA: Column 1: Biotinylated 
kininogen (bHK) binds immobilized MPO but not BSA as detected by alkaline 
phosphatase-conjugated streptavidin; Column 2: bHK binding is reduced in the 
presence of excess unlabeled kininogen (uHK); Column 3:  Unlabeled kininogen alone 
was negative.  b) Sandwich ELISA: further validation of the direct interaction 
between MPO and kininogen. Column 1: monoclonal MPO antibody-captured MPO 
binds bHK as detected by alkaline phosphatase-conjugated streptavidin; Column 2: 
Competition of bHK binding in the presence of excess uHK; Column 3: Unlabeled 
kininogen alone was negative.  Shown are the averaged results of three independent 
trials +/- standard deviations.  c) Sandwich ELISA: validation using a second MPO 
antibody. Column 1: polyclonal MPO antibody-captured MPO binds bHK as detected 
by alkaline phosphatase-conjugated streptavidin; Column 2: Competition of bHK 
binding in the presence of excess uHK; Column 3: Unlabeled kininogen alone was 
negative.  Shown are the results of three independent trials +/- standard deviations.  d) 
MPO captures bHK from plasma.  HK-depleted plasma was replenished with bHK to 
physiologic levels.  Immobilized MPO was used as bait to capture bHK from plasma.  
Shown are the results (with standard error bars) of three independent experiments.   
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Figure 1.6. MPO Interferes with the Plasma Kallikrein-Kinin System: 
Bradykinin Production is Diminished. a) MPO interfered with bradykinin 
production through steric hindrance at high concentrations.  Shown are the results of 
four independent experiments measuring the bradykinin liberated from 50 nM HK in 
the presence of MPO.  b) Provided with its substrate (H2O2), MPO affects bradykinin 
production at lower concentrations.  Shown are the results of three independent 
experiments.  c) The enzymatic activity of MPO (conversion of H2O2 to HOCl) 
hinders bradykinin production, which is rescued in the presence of catalase.  Shown 
are the results of three independent experiments.   
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Figure 1.7. Hypochlorous Acid Inhibits Bradykinin Production. a) The 
proteolytic activity of kallikrein is abolished by HOCl dose-dependently, but is 
protected when HOCl is quenched with L-methionine (20-fold molar excess).  Shown 
are the results (with standard deviations) of three separate experiments.  b) HK is 
oxidized by HOCl resulting in a product uncleavable by active kallikrein.  HK was 
pre-treated with increasing concentrations of HOCl.  A 20-fold excess of L-
methionine was added (20 min) prior to addition of active kallikrein.  Bradykinin 
production was assessed by ELISA. Shown are the results from four separate 
experiments.  c) HOCl inactivates kininogen by oxidizing a critical methionine 
residue.  HOCl-oxidized HK was treated with a methionine sulfoxide reductase (PilB), 
and the inhibition of bradykinin production was reversed.    
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DISCUSSION 
MPO has long been viewed to function primarily as a bactericidal enzyme.  A new 
paradigm presented here extends this perspective and suggests that MPO is profoundly 
involved in the regulation of cellular homeostasis, and may play a central role in the 
regulation of vasodilatation through direct interactions with components of the kallikrein-
kininogen system (diagrammed in Figure 1.8).  We propose that in the inflammatory 
microenvironment, MPO is internalized by endothelial cells through a direct interaction with 
the endothelial surface protein CK1 (Figure 1.8a), known as a scaffold for the plasma 
kallikrein-kinin system.[122, 125] CK1 appears to tether MPO into close proximity of HK and 
the two proteins are internalized in complex (Figure 1.8c).  Moreover, MPO and HK form a 
complex such that blocks the HK site normally cleaved by kallikrein (Figure 1.8d).  In 
addition, MPO’s peroxidase activity causes oxidation and inactivation of HK protein (Figure 
8e) and inactivates plasma kallikrein’s activity (Figure 1.8f).  The end result is a reduction in 
bradykinin liberation from HK (Figure 1.8g). Manipulations of bradykinin levels at sites of 
inflammation could have profound effects on vascular tone and other mediator functions of 
bradykinin. 
Of central importance is the finding that CK1 facilitates MPO internalization by 
endothelial cells.  This is in concordance with reports that MPO uptake is energy-dependent, 
a characteristic of receptor-mediated endocytosis.[29] Cytokeratins are typically thought of as 
structural intermediate filaments, though descriptions of the functions of CK1 in endothelial 
cells imply that it is more than merely structural.  CK1 functions as part of the cells’ 
environmental response pathways sensitized to oxidative stress; endothelial CK1 surface 
protein expression is upregulated in such conditions.[125, 134] While this is the first 
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report of a specific endothelial MPO-binding protein, multiple groups have investigated the 
entry of free MPO into endothelial cells.  In our study, internalized MPO was not exclusively 
localized to CK1, suggesting other possible mechanisms for cell association and trafficking 
of MPO.  Cell surface glycosaminoglycans have been implicated in MPO internalization.[29] 
Additionally, MPO binds to albumin through both sequence- and charge-specific 
mechanisms; the albumin-bound MPO is nonspecifically internalized by albumin-binding 
proteins.[36] However, our group and others have observed substantial MPO internalization 
in albumin-free conditions, supporting CK1-binding as a mode of entry. 
MPO, because it is highly cationic, is often argued to interact with the endothelium 
solely through charge-based interactions.  The mechanism through which CK1 and MPO 
interact is yet to be determined.  In light of the reports that HK is not internalized when 
bound to CK1 through its cationic domain 5, we would argue that internalization of CK1-
bound MPO is unique and specific.[135, 136] This would be fundamentally different from 
mechanisms mediating MPO’s adherence to endothelial cell-surface glycosaminoglycans or 
its internalization coupled to albumin. 
We questioned whether MPO and HK reside on CK1 together or whether they 
compete for binding.  The data support cooperative binding on cells, which would tether 
MPO and HK into close proximity.  For reasons yet to be determined, MPO caused a 
substantial increase in cell-bound HK.  One speculation is that MPO is transporting HK to 
additional sites for binding; MPO can bind through both CK1-dependent and independent 
interactions.  It is tempting to speculate that investigators will find additional situations 
where MPO and HK functionally overlap.  For example, it was reported that MPO and HK 
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individually bind CD11b/CD18 integrin and interestingly, the outcomes were functionally 
opposing.[137-139] 
The ultimate biologic mediator produced by the plasma kallikrein-kinin system is the 
vasoactive peptide bradykinin, which is cleaved from HK by kallikrein. Bradykinin binds at 
least two endothelial receptors to induce vasodilation and an anti-thrombotic state by 
stimulating endothelial nitric oxide production, prostacyclin synthesis, and tissue 
plasminogen activator release.[130, 140, 141] Although MPO increases HK bound to endothelial 
cells, we do not believe this augmentation correlates with increased bradykinin production 
based on our studies.  It may be that MPO binding and internalization of HK serves to 
sequester HK from kallikrein and hinder HK’s effector functions in the inflammatory milieu.  
Beyond the physical interference of MPO with the HK-kallikrein interaction, there was 
strong evidence that protein damage caused by the methionine-specific oxidizing agents 
produced by MPO could be responsible for decreased bradykinin production.[50, 133] There 
was a direct effect of biologically relevant concentrations of HOCl on kallikrein protease 
activity, and the oxidation of HK rendered it resistant to kallikrein proteolysis.  HOCl 
concentrations below 15 µM are sublethal, whereas activation of the endothelial apoptosis 
machinery begins at a 30-50 µM dose and oncotic cell death is provoked above 100 µM.[51] 
The data show that even sublethal concentrations of HOCl overtly affect the ability of this 
system to produce bradykinin, and doses beyond 25 µM totally inhibited bradykinin 
production (not shown).  HOCl is a highly reactive oxidant, so the proximity of MPO to HK 
resulting from their direct interaction and their shared interaction with CK1 could be very 
important when considering these experimental results.[17] 
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During acute and chronic inflammatory states, MPO is released into the vessel wall 
and is functional, based on published studies demonstrating chlorotyrosine in vessel walls.[44] 
Only MPO can mediate this chemistry under physiologic conditions.  Given the large amount 
of MPO per neutrophil (5% of the dry weight), the large number of neutrophils infiltrating 
during acute inflammation, and the altered flow in vessels associated with procoagulant 
activity, we propose that concentrations of MPO in the inflammatory milieu can approach the 
500mM range utilized in these studies.[3] Furthermore, in this microenvironment, the data 
indicate the potential for MPO-kininogen interactions to interfere with the kininogen-
kallikrein process. The effects of MPO’s enzymatic activity could be even more pronounced 
than we are reporting if nitration of tyrosine residues affects kininogen processing.[29, 142] 
MPO can mediate tyrosine nitration in inflammatory conditions through a reaction with 
nitrite, a stable end-product of nitric oxide metabolism.  A hydrogen peroxide dependent 
reaction, nitrite is oxidized by MPO to form the nitrogen dioxide radical, a species capable of 
nitrating both free and protein-bound tyrosines.[25, 26] Such reactions have been associated 
with the inactivation of endothelial angiotensin-converting enzyme as well as the structural 
alteration of endothelial matrix-associated fibronectin.[25, 28, 29] 
Previous studies showed that MPO remains active following internalization and 
catalytically consumes NO, thereby limiting the endothelial vasodilatory response.[24] In 
comparison, our work unveils a mechanism whereby MPO may prevent endothelial NO 
generation in the inflammatory milieu by limiting the production of bradykinin, the most 
potent known inducer of endothelial NO. 
A limitation of these studies is the lack of an in vivo or ex vivo model to demonstrate 
that MPO can interfere with bradykinin production and thus impair vascular function.  
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Although observed in a cellular system, it is difficult to extrapolate the consequences of the 
MPO and CK1 interaction to the inflamed tissue environment.  This question will be a focus 
of future studies.  Another point that needs further exploration is the composition of the 
internalized CK1, MPO, and/or HK complexes.  
In summary, CK1 is an endothelial receptor that aids in the internalization of MPO.  
Additionally, MPO directly interacts with HK, which also binds CK1 protein. The products 
of MPO’s enzymatic activity can oxidize and inactivate both HK and plasma kallikrein.  The 
collective interactions between MPO and the plasma kallikrein-kinin system result in a 
decrease in bradykinin production.  Whether the molecular interactions discovered here are 
part of the normal processes of an inflammatory response or whether they are 
pathophysiological mediators of organ injury, or both, is yet to be determined.  It may be that 
leakage of small amounts of MPO localized at the vessel wall play a role that is ultimately 
beneficial to the host.  The converse may be true when MPO is released in excess quantities 
during inflammation.  Regardless, the importance of MPO in vascular biology is further 
demonstrated by these studies.  
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ABSTRACT 
The Theory of Autoantigen Complementarity implicates proteins complementary in 
sequence and/or structure to autoantigens as a cause of autoimmune disease.  In this chapter, 
we demonstrated that MPO-ANCA patients have antibodies specific to a recombinant 
complementary MPO protein.  The presence of these antibodies is consistent with the 
development of MPO-specific antibodies as a result of an anti-idiotypic response against the 
anti-complementary antibody.  We could not optimally test this hypothesis using human 
patient material.  Thus, we used a mouse model of MPO-ANCA glomerulonephritis, 
attempting to induce disease through immunization with recombinant complementary 
proteins and synthetic peptides.  Though these models were unsuccessful, they allowed us to 
rule out potential pathogenic epitopes.  A mass spectrometry-based epitope mapping 
technique was employed to determine the murine MPO epitope recognized by disease-
causing anti-murine MPO antibodies.  This technique revealed a 24 amino acid peptide.  
However, this peptide was minimally immunogenic and anti-peptide antibodies did not cross-
react with native murine MPO.  While it appears that human patients were exposed to a 
complementary MPO protein some time along their disease course, proving causation in an 
animal model will be a challenge until pathogenic epitopes and interacting complementary 
proteins are identified. 
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INTRODUCTION 
The origins of autoimmune disease remain elusive, though increasing evidence 
suggests that complementary proteins play a role.  The Theory of Autoantigen 
Complementarity, as proposed by our group, begins with the exposure to a peptide or protein 
that is complementary in sequence and/or shape to a known autoantigen.  This 
complementary antigen is recognized as foreign to the host and elicits a humoral response.  
The idiotypic network of antibody regulation is initiated, and an anti-antibody is generated 
whose binding site reflects the “internal image” of the complementary protein; therefore, this 
anti-antibody is an autoantibody that cross-reacts with the autoantigen leading to disease 
manifestations.    In support, we and others have demonstrated an intact idiotypic network in 
patients with autoimmune disease, implying that the patients with PR3-ANCA, systemic 
lupus erythematosus, and Sjogren’s syndrome may have been exposed to a complementary 
autoantigen prior to the onset of disease.[73, 110] Pendergraft et al have recapitulated the 
idiotypic network in vivo by showing that mice immunized with a complementary PR3 
peptide developed an antibody reactive to PR3.   
There is an old saying, “Which came first: the chicken or the egg?”  This remains an 
outstanding question relative to studies implicating the idiotypic network in autoimmunity.  
With regards to PR3-ANCA, do patients harbor the anti-complementary PR3 antibody 
primarily as a result of the immune response generated against complementary PR3, or did 
this anti-complementary PR3 antibody develop secondarily as an anti-idiotype to the 
autoantibody. The latter suggests the presence of anti-complementary PR3 antibodies is 
merely an epiphenomenon.  Importantly, animal models suggest the former is possible, 
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however there exist no studies in which disease is induced in an animal model by the 
immunization of a complementary autoantigen.   
The work in Chapter 2 attempts to broaden the support for our Theory of Autoantigen 
Complementarity.  We asked if there was evidence of an immunological encounter with a 
complementary protein in MPO-ANCA patients, as was seen in PR3-ANCA patients.  We 
found that a subset of MPO-ANCA patients harbor antibodies specific for a recombinant 
complementary MPO polypeptide, substantiating the general applicability of this proposed 
mechanism.  Are these anti-complementary MPO antibodies involved in the pathogenesis of 
the disease?  The major goal of this study was to induce disease in an MPO-ANCA mouse 
model by producing pathogenic anti-MPO IgG through immunization of the mice with 
several complementary MPO antigens.  Additionally, a new epitope mapping technique was 
employed to define a pathogenic MPO epitope using anti-MPO antibodies that cause disease 
in mice.  
 
MATERIALS AND METHODS 
Antibodies, Antigens, and Reagents 
The His-probe (Rabbit anti-histidine fusion peptide) antibody was from Santa Cruz 
Biotechnology (Santa Cruz, CA), the rabbit anti-MPO antibody was from DAKO 
(Carpinteria, CA), the horseradish peroxidase goat anti-rabbit IgG antibody was from 
Chemicon (Temecula, CA), and the alkaline phosphatase-conjugated goat anti-rabbit IgG 
antibody was from Pierce Biotechnology (Rockland, IL).  Alkaline phosphatase-conjugated 
goat anti-human IgG and donkey anti-mouse IgG were purchased from Jackson 
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Immunoresearch Laboratories (West Grove, PA). The alkaline phosphatase substrate kits 
were purchased from Bio-Rad Laboratories (Hercules, CA) or Pierce Biotechnology, and the 
Western Pico Chemiluminescent Peroxidase Substrate Kit was from Pierce Biotechnology.   
Native murine MPO was prepared from WEHI cells as previously described, and 
generously provided by Hong Xiao.[69] Bovine Serum Albumin was purchased from New 
England Biolabs (Beverly, MA).  Fish gelatin was from Sigma (St. Louis, MO).   
Murine MPO and complementary MPO peptides were ordered from Alpha Diagnostic 
International (San Antonio, TX). 
 
Cell Culture 
HEK 293 cells were grown in DMEM-F12 supplemented with 2 mM L-Glutamine, 
5% heat-inactivated fetal bovine serum (Sigma, St. Louis, MO), penicillin/streptomycin, and 
Genetecin for selection when needed.  All reagents were from Gibco (Invitrogen, Carlsbad, 
CA)   
 
Human Recombinant cMPO proteins:  Site-directed Mutagenesis, Subcloning, and 
Recombinant Protein Production  
 
Two complementary MPO (cMPO) proteins were created for these studies.  Upon 
analyzing the antisense mRNA sequence of MPO in a 5’3’ direction, we found that the 
antisense codon corresponding to serine 485 was a STOP signal.  Therefore, we utilized 
Strategene’s QuikChange II XL Site-Directed Mutagenesis Kit (La Jolla, CA) to mutate the 
last base of the serine-485 codon from “a” to “c” in order to change the complementary 
amino acid from a termination signal to an glycine.  The instructions provided with the kit 
were followed to produce the MPO cDNA mutant.  Human MPO cDNA was used as the 
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starting material for site-directed mutagenesis. The forward primer sequence used to generate 
mutated MPO cDNA was 5’TCCTACAATGACTCCGTGGACCCACGCATC-3’ and the 
reverse primer sequence was 5’GATGCGTGGGTCCACGGAGTCATTGTAGGA-3’.  
To create plasmids containing the antisense MPO sequence as the sense strand of the 
plasmid, we created PCR primers containing endonuclease restriction sights that would allow 
us to amplify specific antisense MPO fragments from the mutated MPO cDNA and insert 
them into a mammalian expression vector. The forward primers contained a HindIII site, and 
the reverse primers contained an XhoI site as well as a STOP codon.  One set of primers 
amplified a complementary MPO polypeptide from the mutated cDNA corresponding to 
sense amino acids 420-697 (cMPO(420-697)): 
5’CCCAAGCTTGATCTGGGCCAGGGCCTGTC-3’ (forward primer sequence) and 5’--
CCGCTCGAGCTACTTCGGGAGCACAACCGGCT-3’(reverse primer sequence).  Another 
set of primers amplified a sequence corresponding to amino acids 279-392 (cMPO(279-
392)): 5’ Cccaagcttgcggttggtgaggagacaggg  3’ (forward primer sequence) and 5’ 
CCGCTCGAGCTAGTCAACTGCGAGACCAGCTGC 3’ (reverse primer sequence).  The 
translated cMPO(279-392) sequence did not contain any STOP signals and did not require 
prior site-directed mutagenesis.  The PCR products were gel purified using Qiagen’s Gel 
Purification Kit (Valencia, CA), and the products and parent plasmid were digested with 
HindIII and XhoI (New England Biolabs, Beverly, MA) to create compatible ends.  The 
digested PCR products were gel purified and ligated into the digested parent plasmid, a 
pcDNA3 eukaryotic expression vector (Invitrogen) previously engineered to express a BM40 
secretion signal peptide and a hexahistidine tag, both C-terminal to the complementary 
protein. 
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The cMPO proteins were produced by electroporating HEK 293 cells with the 
appropriate vectors using a Bio-Rad Gene Pulser.  The cells were placed in Genetecin-
containing media to select for cells containing the cMPO plasmids.  The surviving cells were 
passaged and expanded into Corning CellSTACK “factories” (Acton, MA) for mass 
production of recombinant protein.  When the cells reached confluence, the medium was 
replaced with serum-free medium for one week.  Expression of the BM40 signal peptide 
induced the cells to secrete the protein into the serum-free medium.  The proteins were 
precipitated from 4 liters of collected cell-free medium with ammonium sulfate (313 g/L) at 
4°C overnight, resuspended, and dialyzed into PBS containing 20mM immidizole.  The 
cMPO proteins were partially purified using HisTrap HP columns (GE Healthcare) and 
analyzed for purity by coomassie-stained SDS-PAGE, and for specificity by immunoblot 
specific for the hexahistidine tag. 
 
Murine Recombinant cMPO Proteins: Site-directed Mutagenesis, Subcloning, and 
Recombinant Protein Production 
 
The murine recombinant polypeptides m-cMPO(460-718) and m-cMPO(253-449) 
were engineered in parallel with the human cMPO recombinant proteins and prepared in the 
exact same manner save for a few changes.  Two mutated m-MPO full length cDNAs were 
prepared, each expressing one mutation; Strategene’s QuikChange II XL Site-Directed 
Mutagenesis Kit (La Jolla, CA) was utilized to introduce an “a” to “c” mutation of the third 
base of the leucine 646 codon in one preparation, and the same mutation was introduced to 
leucine 323 in another; these mutations changed the complimentary STOP signals to 
glutamic acids.  The primers used for the site-directed mutagenesis were: 
5'CTCAGTTTAGGAAGCTCCGTGATGGTGATCGGTT-3' (L646 forward), 
64
5'AACCGATCACCATCACGGAGCTTCCTAAACTGAG-3' (L646 reverse), 
5'CTCAGTTTAGGAAGCTCCGTGATGGTGATCGGTT-3' (L323 forward), and 
5'AACCGATCACCATCACGGAGCTTCCTAAACTGAG-3' (L323 reverse). The 
instructions provided with the kit were followed to generate mutated MPO cDNAs, and the 
UNC Genome Analysis Facility verified the sequence of each.  To PCR amplify the cDNA 
fragments encoding our m-cMPO proteins from the mutated MPO cDNA, one set of primers 
amplified a complementary murine MPO polypeptide corresponding to sense amino acids 
460-718 (m-cMPO (460-718)), and the other set corresponded to sense amino acids 253-449 
(m-cMPO(253-449)).  The primer sequences were: 
5’CCCAAGCTTGGTCTCCTTCCAGGAAGTCA-3’ (m-cMPO(460-718) forward), 
5’CCGCTCGAGCTAGTAGACCCTCGAATCGCCAA-3’ (m-cMPO (460-718) reverse), 
5’-CCCAAGCTTGGTCTCCTTCCAGGAAGTCA-3’ (m-cMPO(253-449)forward), and 
5’CCGCTCGAGCTAGTAGACCCTCGAATCGCCAA-3’ (m-cMPO(253-449) reverse).  
All of the other methods involving production of the m-cMPO proteins were identical to 
those for human cMPO. 
 
ELISAs to Determine Whether Patients Harbored Antibodies Reactive with cMPO(420-697)  
An initial screen was conducted to compare MPO-ANCA patient reactivity (n=25) 
against cMPO(420-697) to a small set of healthy control sera (n=5).  Afterwards, another set 
of patients (n=19) was screened and compared to a different, and larger, set of healthy 
controls (n=26) to increase the statistical power of the experiment.  One patient sample was 
repeated in both experiments.   
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Prior to performing the ELISAs, it was determined that the cMPO(420-697) could be 
diluted by half prior to coating the ELISA wells with only modest loss of reactivity using the 
His-probe (not shown).  ELISA wells were coated overnight with rocking at 4°C with 
cMPO(420-697), MPO at 5 µg/ml, or 0.5% Fish gelatin solution as a sham; all dilutions were 
in ELISA coat buffer.  Between all subsequent steps, the wells were washed at least 3 times 
with a PBS-Tween solution.  The wells were blocked with 1% fish gelatin buffer for 2 hours 
at room temperature.  Healthy control and ANCA patient sera were spun at 10,000 RPM for 
10 minutes at 4°C to remove aggregates and precipitate prior to use.  The sera were diluted 
1:100 in the fish gelatin buffer and incubated in the wells for 2 hours at room temperature.  
The secondary antibody was added to the wells for 1 hour at room temp followed by the 
addition of substrate for 1 hour.  The wells were read in a microplate reader at OD 405 nm. 
Patients were considered positive for reactivity to cMPO(420-697) if their OD 405 
was higher than 2 standard deviations above the mean OD 405 of the normals.    
 
Murine Recombinant Protein Immunizations and Serum Collection 
Approximately 100 µl of blood was collected from MPO -/- mice on a C57BL/6J 
background by tail nicks prior to immunizations.  The blood was allowed to clot for at least 
one half hour at room temperature and then spun in a microcentrifuge at 10,000 RPM for 10 
minutes to separate the serum from the clot.  The serum was collected and stored at -20°C for 
later use. 
Partially purified recombinant m-cMPO was dialyzed in PBS, and mixed into an 
emulsion in a 1:1 ratio with TiterMax (Norcross, GA).   Each mouse was immunized 
intraperitoneally with 200 µl of the emulsion; each mouse received 100 µl of the partially 
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purified m-cMPO that was at an approximate concentration of 19 µg/ml.  The negative 
control mice received 10 µg of BSA and the positive control mice received 10 µg of native 
murine MPO, both in the same volume as the m-cMPO injections.   The same immunogens 
were prepared in TiterMax for boost immunizations at weeks 2 and 6.  The boost 
immunizations were injected intramuscularly at the tail base, 100 µl each on both sides of the 
tail.  The appropriate mice received 100 µl of the partially purified m-cMPO, and 10 µg of 
MPO and BSA were delivered to control mice. The mice were bled weekly, and the blood 
was processed to obtain serum as described above.   Each set of mice had a mix of males and 
females. 
 
ELISA to Analyze for the Induction of the Idiotypic Network 
Prior to performing ELISAs to analyze serum reactivity to m-cMPO, a direct ELISA 
determined that m-cMPO could be diluted 25-fold and still be recognized by the His-probe 
antibody, with only 15% less reactivity compared to a neat m-cMPO solution (data not 
shown). 
ELISA wells were coated with either 50 µl each of m-cMPO diluted 1:25, 5 µg/ml 
native murine MPO, 5 µg/ml BSA, or coat buffer only at 4°C with rocking overnight; all 
dilutions were in ELISA coat buffer.  The wells were blocked with 150 µl of a 1% fish 
gelatin solution for 1 hour at room temperature.  The mouse serum was centrifuged at 5,000 
RPM for 10 minutes at 4°C prior to usage to remove any immunoglobulin aggregates or 
precipitate.  The serum was diluted 1:100 in the fish gelatin solution and 50 µl was added to 
the wells for 2 hours with rocking at room temperature.  Fifty µl of 1:2500 diluted alkaline 
phosphatase-conjugated secondary antibody was added to the wells for 1 hour at room 
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temperature, followed by substrate.  The wells were washed at least 3 times between each 
step.  Following substrate exposure for 1 hour, the ELISA plates were read at 405 nM. 
 
Sense and Complementary Peptide Immunizations and Serum Collection 
Approximately 100 µl of blood was collected from MPO -/- mice on a C57BL/6J 
background by tail nicks prior to immunizations.  The blood was allowed to clot for at least 
one half hour at room temperature and then spun in a microcentrifuge at 10,000 RPM for 10 
minutes to separate the serum from the clot.  The serum was collected and stored at -20°C for 
later use. 
The initial immunizations were delivered in Freund’s complete adjuvant (Difco 
Laboratories, Detroit, MI), and each set of mice received 100 µg of total protein.  One set of 
mice (n=5) received 50 µg of each antisense peptide, m-cMPO(484-508) and m-cMPO(694-
718).  One set of mice (n=5) received 50 µg of each corresponding sense peptide, m-
MPO(484-508) and m-MPO(694-718).  Another set of mice received both pairs of sense and 
antisense peptides.  M-MPO(484-508) and m-cMPO(484-508) were mixed in PBS at room 
temp for 1 hour to form a sense-antisense peptide pair, as were peptides m-MPO(694-718) 
and m-cMPO(694-718). The two pairs of peptides were then mixed together and emulsified 
in Freund’s adjuvant for delivery.  The negative control mice included a set (n=4) that 
received 100 µg BSA set, and 2 positive control mice were immunized with 10 µg native m-
MPO.  All mice were immunized intraperitoneally, and all sets had a mix of males and 
females.   
The boost immunizations were carried out in Freund’s incomplete adjvant, also 
delivered intraperitoneally, at weeks 4 and 8.  These boosts used exactly half the amount of 
68
proteins as the initial immunizations with the exception of the 10 µg of native m-MPO used 
in the positive controls.  Serum was collected and stored weekly as described above. 
 
Splenocyte Transfer, Urine, Serum, and Tissue Collections 
Splenocytes were isolated from all immunized sets of MPO -/- mice by disrupting the 
pooled spleens into cold RPMI 1640 medium and then washing twice with the medium.  Red 
blood cells were removed with lysis buffer (Sigma, St. Louis, MO) followed by washing with 
cold RPMI 1640, and the splenocytes were resuspended in sterile PBS for injection.  A 
suspension of 1 X 108 splenocytes in 500 µl of PBS was delivered intravenously to each 
RAG-2 -/- mouse.  Males and female mice were mixed in each set (n=4), and each set 
reflected the initial immunization scheme (i.e. one set of RAG-2 -/- mice received 
splenocytes from the m-cMPO peptide immunized MPO  -/- mice, etc.).  There were only 2 
positive control RAG-2 -/- mice that received splenocytes from the native m-MPO-
immunized MPO -/- mice.  
The RAG-2 -/- mice were bled as described above (including a bleed prior to the 
splenocyte transfer) on Days 7, 10, and 17.  Mice were immobilized on Day 16 and directly 
urinated on a dipstick to test for hematuria.  On Day 12, the positive control mice appeared 
physically ill and were anesthetized with Avertin for euthanasia.  All other RAG-2 -/- mice 
were euthanized on Day 18.  The mice were terminally bled and samples of their kidney, 
lung, spleen, and liver were fixed in 10% formalin and processed for light microscopy.  All 
specimens were stained with hematoxylin and eosin (H&E) and periodic acid Schiff (PAS) 
stains.  Pathologic evaluation was carried out without knowledge of the experimental 
conditions. 
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ELISA to Analyze the Induction of the Idiotypic Network in Peptide-immunized MPO 
Knockout Mice 
ELISA plates used for the MPO -/- mice were coated overnight at 4°C with either 10 
µg/ml sense MPO peptides (5 µg/ml of each sense MPO peptide mixed), 10 µg/ml 
complementary MPO peptides (5 µg/ml of each complementary MPO peptide mixed), 5 
µg/ml native murine MPO, or 1% goat serum as a sham.   ELISA wells used to analyze the 
RAG-2-/- mice used a total peptide concentration of 5 µg/ml and 5 µg/ml fish gelatin as a 
sham.   The wells were rinsed after coating (and after every subsequent step) with at least 3 
washes of a PBC-Tween solution.  For the MPO  -/- mice the wells were blocked with 1% 
goat serum, and the wells for the RAG-2-/- were blocked with 1% fish gelatin (the blocking 
solutions for each respective experiment also served as the antibody diluent).  The wells were 
blocked at least 2 hours at room temperature.  The serum from each mouse was centrifuged 
at 10,000 RPM for 10 minutes at 4°C.  Serum was diluted 1:100 in the appropriate diluent 
and applied to the wells at room temperature for 2 hours.  Secondary antibody was applied 
for 1 hour at room temperature followed by the addition of substrate for 1 hour. 
 
Epitope Mapping Pathogenic Murine Anti-MPO Antibodies 
A collaboration to epitope map the pathogenic murine MPO-ANCA by a combination 
of epitope excision and Matrix-assisted laser desorption/ionization (MALDI)-mass 
spectrometry (MS) was established with the UNC-Duke Michael Hooker Proteomics Center, 
as described in Parker et al.[143] Briefly, total IgG containing pathogenic ANCA was 
prepared by pooling sera from terminal bleeds of 3 different MPO -/- mice that had been 
immunized with native murine MPO.  The pooled sera were filtered through a 0.22µm filter 
and passed over a HiTrap Protein G Column (GE Helthcare) to purify total IgG.  The total 
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IgG was immobilized on CNBr-activated Sepharose beads.  Affinity-purified murine MPO 
was linked to the immobilized antibodies and submitted for analysis.  The murine MPO was 
affinity purified using the DAKO rabbit anti-human MPO, which recognized mouse MPO. 
A series of proteolytic steps were used to cleave fragments from the immobilized 
antibody-bound MPO; the epitopes attached to the antibody are protected from proteolysis 
and stay attached to the antibody.  The beads are then washed and the MALDI matrix 
solution desorbs the bound fragment from the immobilized antibody.  This fragment(s) is 
subjected to MALDI analysis to determine which peptides are left bound to the antibody 
following each digestion step.  This can be accomplished because the immobilized antibodies 
themselves are fairly resistant to proteolysis, perhaps due to its high glycosylation status.[143] 
A list of predicted enzyme cleavage sites can be generated for each peptidase used, and one 
can compare the resulting MALDI mass spectrum obtained from the analysis to the predicted 
cleavage fragments to identify the antibody-bound fragment.  The initial enzyme used was 
endoproteinase Lys-C, an infrequent cutter that generated “reasonably” sized fragments to 
identify.  Subsequently, trypsin-TPCK is used to further hone the bound eptitope.  Finally, 
the beads are subjected to carboxypeptidase Y digestion for fine-scale mapping of the C 
terminus, and aminopeptidase M for the N terminus.  The results are confirmed by MS/MS, 
comparing spectra from the antibodies alone to the antibodies with digested MPO bound. 
 
m-MPO(302-325) Peptide Immunizations and Serum Collection 
MPO null mice were pre-bled as described above.  One set of mice (n=3) was 
immunized with 50 µg of the epitope mapped peptide, m-MPO(302-325), prepared in 
Complete Freund’s Adjuvant.  Two mice were immunized with adjuvant alone as a sham 
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control, and one mouse was immunized 10 µg native murine MPO as a positive control.  
Mice were bled weekly by tail nicks as described above.   
The m-MPO(302-325) mice were boosted at week 4 with 75 µg peptide prepared in 
Incomplete Freund’s Adjuvant.  The shams were immunized with adjuvant alone and the 
positive control was boosted with 5 µg murine MPO. 
 
ELISAs to Analyze Anti-m-MPO(302-325) Antibody Cross-reactivity with Native MPO 
ELISA plates were coated with 5 µg/ml murine MPO, 10 µg/ml m-MPO(302-325) 
peptide, or 5 µg/ml fish gelatin overnight at 4°C overnight.  Each well was blocked for 2 
hours at room temperature with 1% fish gelatin buffer.  Serum samples were prepared by 
centrifuging at 12,000 RPM for 10 minutes and then diluted 1:100 in the fish gelatin buffer.  
The wells were exposed to the sera for 2 hours at room temperature, followed by the alkaline 
phosphatase-conjugated donkey anti-mouse secondary at a 1:3500 dilution for 1 hour.  
Substrate was applied and the plate incubated at 4°C overnight and read at 405 nM the 
following morning. 
Prior to conducting a competition ELISA, the dilution at which the MPO-immunized 
mouse serum and pooled total IgG (of 3 MPO null mice immunized with MPO) had 50% 
reactivity against native murine MPO was determined.  The pooled total IgG was the same 
used to epitope map the m-MPO(302-325) peptide.  ELISA plates were coated for 2 hours at 
37°C, and then blocked with 1%  fish gelatin for 1 hour at room temperature.  A 5-fold 
dilution series starting at a 1:25 dilution, and a 1:2 dilution series starting at 1:50, was 
prepared using the serum and total IgG in the fish gelatin buffer.  The serum sample had 50% 
reactivity at 1:3000 dilution and the total IgG at 1:8500.   For the competition 
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ELISA, the wells were coated 5 µg/ml murine MPO or fish gelatin.  The wells were blocked 
with fish gelatin for 2 hours at room temperature.  The antibody solutions were prepared at 
the dilutions mentioned above in the presence of 6.25 to 100 µg/ml m-MPO(302-325) 
peptide for 1 hour 45 minutes at room temperature before being applied to the wells for 1 
hour.  A nonspecific, competition control peptide was used that corresponded to 
complementary proteinase 3.  The secondary antibody was applied for 1 hour at room 
temperature, followed by substrate and readings at 405 nM. 
 
RESULTS 
Rationale for the Design of Human Recombinant MPO 
There was no defined pathogenic epitope for human MPO-ANCA for which to design 
a correlating complementary protein.  However, epitope mapping studies by our lab and 
others revealed an immunodominant region consisting of 230 amino acids in the C-terminus 
of the heavy chain, so we focused our efforts on this region of human MPO.[144, 145] We 
decided to engineer a large, 278 amino acid cMPO polypeptide corresponding to sense amino 
acids 420-697, roughly covering the entire C-terminal half of the heavy chain (Figure 2.1). 
Unfortunately, translation of the antisense strand of MPO cDNA (read 5’ 3’) revealed 
multiple STOP codons, including one at sense amino acid serine-698.  We decided to utilize 
site-directed mutagenesis to mutate the wobble base of serine-698 to change the antisense 
codon from a STOP to a glycine, allowing us to produce the cMPO(420-697) polypeptide in 
full. While cMPO(420-697) may not be translated as such in vivo, it allowed us to 
incorporate the entire C-terminal half of the heavy chain, thus providing as many 
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conformational complementary epitopes as possible in one protein.  The epitope mapping 
study by Fujii et al both confirmed that the C-terminal of MPO was immunodominant, and 
revealed an ANCA-reactive region in the N-terminus of the heavy chain; an additional 
complementary protein was constructed corresponding to this region, amino acids 279-392.  
Together, the two cMPO polypeptides we produced span the majority of the MPO heavy 
chain sequence as diagramed in Figure 2.1.   
A Subset of MPO-ANCA Patients have Antibodies Specific for cMPO(420-697) 
An initial ELISA screen was conducted following the first round of cMPO(420-697) 
purifications.  Because a limited amount of protein was purified, we screened more patients 
than healthy controls to gain insight as to whether this protein would be recognized in the 
patient population.  We found 7 of 25 patients tested in this initial screen were reactive to the 
cMPO(420-697) protein (Figure 2.2).  Though tantalizing, the results were statistically 
insignificant due to the low numbers of normals (5) tested (p value = 0.55 using Fisher’s 
Exact Test).  
A second screen was conducted analyzing more healthy controls (n=25) than patients 
(n=19).  In this screen, 6 of 19 patients were positive and these results were statistically 
significant (p value = 0.03 using Fisher’s Exact Test) (Figure 2.3).  Two positive samples in 
this ELISA were from patients that tested positive in the initial screen; one sample was an 
exact repeat, and the other was from the same patient drawn on a different date.  
Interestingly, the cMPO(420-697) antibody seems to have persisted in this patient over 
several months.   
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Figure 2.1.  Design and Production of Recombinant Complementary 
Myeloperoxidase Polypeptides.  We produced complementary protein fragments 
encoded by the antisense sequence (read 5’  3’, in frame) of the MPO gene, 
corresponding to sense amino acids 420-697 [cMPO(420-697)] and 279-392 
[cMPO(279-392)].  Several STOP codons were introduced when translating the 
antisense sequence; site-directed mutagenesis was employed to mutate the 3rd base in 
the serine 485 codon (TCATCC) to change the antisense STOP to a glycine residue.  
This cDNA was inserted into a vector and transfected into a HEK 293 cell secretion 
system.  The expressed recombinant protein fragments contain an amino-terminal 
histidine tag for purification and immunodetection.  Inset is an immunoblot of the 
purified recombinant proteins, using an anti-histidine tag antibody.  
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Figure 2.2.  An Initial Screen Reveals that MPO-ANCA Patients may have 
Antibodies Reactive with cMPO(420-697).  MPO-ANCA patient (n=25) and healthy 
control (n=5) sera were screened for reactivity against cMPO(420-697).  The mean 
OD value of the healthy controls was 0.17 (dashed line).  Patients are considered 
positive if their sera results in an OD405 greater than 0.34, two standard deviations of 
the mean of the healthy controls (solid line).  A p-value of 0.55 was acquired using 
Fisher’s Exact Test, meaning that the results of this ELISA were insignificant due to a 
low number of control samples. 
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Figure 2.3.  MPO-ANCA Patients have Antibodies Reactive with cMPO(420-697).  
MPO-ANCA patient (n=19) and healthy control (n=26) sera were screened for 
reactivity against cMPO(420-697).  The mean OD value of the healthy controls was 
0.29 (dashed line).  Patients are considered positive if their sera results in an OD405 
greater than 0.53, two standard deviations of the mean of the healthy controls (solid 
line).  A p-value of 0.03 was acquired using Fisher’s Exact Test, meaning that the 
patient values over 0.52 are statistically significant, and indicated by the star. 
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Rationale for the Design of Recombinant Murine MPO 
The murine anti-MPO antibodies that caused disease in the MPO-ANCA 
glomerulonephritis mouse model were not epitope mapped.[69] As there was not a defined 
pathogenic epitope for murine MPO, we correlated information from human studies to design 
our potentially pathogenic m-cMPO.  Our two recombinant m-cMPO proteins were designed 
similar to the human sequences, together spanning the majority of the m-MPO heavy chain; 
this is based on the assumption that, as in humans, the murine MPO heavy chain harbors the 
major antigenic region(s).   
Like the human sequence, analysis of the translated protein sequence from the 
antisense m-MPO RNA revealed several stop codons (Figure 2.4).  Where leucine 323 and 
646 are coded in the sense strand by a “cta” codon, translation of the corresponding 5’3’
antisense sequence (“tag”) codes for a STOP codon.  We decided to mutate the “wobble” 
bases of the leucine 323 and leucine 646 codons in order to change the corresponding 
antisense stop codons to glutamic acids. While m-cMPO(460-718) and m-cMPO(253-449) 
may not be translated as such in vivo, it allowed us to incorporate the entire c- and n-termini 
of the heavy chain; these regions were previously shown to have ANCA reactivity in human 
patient samples.  
Production and Purification of m-cMPO(460-718) 
The recombinant protein was partially purified using nickel chromatography and 
analyzed for purity by coomassie-stained SDS-PAGE.  Three column elution fractions 
contained the majority of the m-cMPO(460-697) protein, as visualized at approximately 
30kD(not shown).  However, these fractions also had a considerable amount of high 
molecular weight contaminating proteins that did not react with the His-probe antibody by 
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western.  We determined the concentration of m-cMPO in the preperation to be 
approximately 19 µg/ml by comparison to known amounts of a control protein.  The 3 
fractions containing the cMPO were combined and utilized for immunizations. 
Mice Immunized with m-cMPO(460-718) did not Produce Anti-MPO Antibodies 
The initial goal of this study was to induce the idiotypic network in MPO-/- mice, so 
that mice immunized with m-cMPO(460-718) would develop anti-cMPO antibodies as well 
as an anti-anti-cMPO antibodies. The anti-anti-cMPO antibodies would be anti-idiotypic 
antibodies that could recognize native mouse MPO.  The ultimate goal of the study was to 
induce pauci-immune glomerulonephritis in MPO +/+ mice by transferring splenocytes from 
the m-cMPO-immunized mice that developed anti-MPO antibodies, thus demonstrating for 
the first time that complementary proteins can induce disease.  Immunized MPO-/- mice sera 
were analyzed for the presence of anti-MPO antibodies over a time course spanning 10 
weeks (Figure 2.5).  Mice were tested for their humoral responsivity to their respective 
immunogens as well; all mice except one BSA control mouse was highly reactive to their 
immunogen.  At no time over the 10-weeks did the m-cMPO-immunized mice generate an 
anti-MPO response above background or when compared to the BSA controls (Figure 2.5c).  
Because of the lack of anti-MPO antibodies, we did not harvest and transfer splenocytes 
using this model.  Though these results were similar when using synthetic peptides, we did 
splenocyte transfers using the peptide-immunized mouse splenocytes, as described below. 
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Figure 2.4.  Design and Production of Recombinant, Complementary Murine 
Myeloperoxidase Polypeptides.  We produced complementary protein fragments 
encoded by the antisense sequence (read 5’  3’, in frame) of the MPO gene, 
corresponding to sense amino acids 460-718 [m-cMPO(460-718)] and 253-449 
[cMPO(253-449)].  Several STOP codons were introduced when translating the 
antisense sequence; site-directed mutagenesis was employed to mutate the 3rd base in 
leucines 323 and 646 codon (CTACTC) to change the antisense STOP to a glutamic 
acid residue.  This cDNA was inserted into a vector and transfected into a HEK 293 
cell secretion system.  The expressed recombinant protein fragments contain an 
amino-terminal histidine tag for purification and immunodetection. Inset is an 
immunoblot of the purified recombinant proteins, using an anti-histidine tag antibody.  
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Figure 2.5.  Mice Immunized with m-cMPO(460-718) did not Produce Anti-MPO 
Antibodies.  MPO knockout mice were immunized with either m-cMPO(460-718), 
murine MPO (m-MPO), or bovine serum albumin (BSA) on weeks indicated by 
arrows.  Sera was acquired weekly and analyzed for reactivity to a) BSA, b) m-
cMPO(460-718), and c) m-MPO by ELISA. 
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Rationale for the Selection of m-cMPO Peptides 
The first experiment, conducted in an attempt to generate anti-MPO antibodies by 
immunizing mice with a complementary MPO protein, was not successful.  This experiment 
used a partially purified recombinant protein that we were unable to produce large amounts 
of in a reasonably concentrated, pure form.  The m-cMPO(460-718) was less than 25% of the 
total protein in the partially purified mixture, and the mice were probably immunized with 
only 2 µg of m-cMPO.  The HEK 293 production system proved highly inefficient and 
expensive for this particular recombinant protein, so we purchased synthesized m-cMPO 
peptides in an effort to acquire highly purified and concentrated antigen.  
Again, there was no defined pathogenic epitope for the disease-causing murine anti-
MPO antibodies, so we gleaned what we knew from human studies to design these peptides.  
Studies from our laboratory showed that despite the 80% amino acid identity between human 
and mouse MPO, the majority of human ANCA do not bind murine MPO.  This implied that 
the pathogenic human epitopes could be in the regions of amino acid sequence dissimilarity, 
and perhaps the same could be said for murine MPO epitopes.  The study by Erdbrugger et al 
identified a broad region at the C-terminus of the MPO heavy chain to be most reactive to 
human patient ANCA.[144] Additionally, a previous graduate student in our laboratory 
attempted to epitope map MPO by producing random protein fragments.  That study revealed 
a region from amino acids 522-683 that reacted with every ANCA tested; however, this 
region also reacted with several normal sera.  When testing another polypeptide 
corresponding to amino acids 550-617, which was internal to the highly reactive 522-683 
fragment, the same ANCA lost much of the reactivity.  Therefore it was determined that the 
highly reactive epitope on the MPO molecule could be between amino acids 522-549, or 
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between amino acids 618-683.  This information was considered and four 25-mer peptides 
were conceptually designed for potential use in these studies.  Using computer based 
molecular modeling software, the peptides were analyzed to predict their surface exposure on 
the MPO molecule.  Murine MPO had not yet been crystallized, however such data did exist 
for human MPO.[146, 147] Analysis of the human regions of MPO homologous to the 
previously designed murine MPO peptides revealed two surface-exposed peptides 
corresponding to amino acids 484-508 and 694-718 (Figure 2.6).  A limitation in this human 
modeling information lied in the fact that the selected mouse peptide sequences diverged 
from the human by 7 out of 25 amino acids in each.  These regions may fold differently in 
the native murine MPO molecule and may or may not be exposed on the surface, as we 
predicted.  Regardless, pairs of sense and complementary peptides corresponding to the 
selected regions were ordered. 
The individual mice in this study were immunized with a set of peptides for multiple 
reasons.  Primarily, because we did not know the pathogenic epitope, this method permitted 
the exposure of multiple epitopes to each animal as we intended to do with the recombinant 
m-cMPO(420-697).  Additionally, work associated with our laboratory was focused on 
creating a monoclonal anti-murine MPO antibody that could induce disease in our MPO-
ANCA animal model.  This work has not yielded disease induction as accomplished via 
passive transfer of total IgG from m-MPO-immunized MPO null mice.  It is thought that, to 
be pathogenic, the antibodies may be polyclonal.  We hypothesized that immunizing with 
multiple peptides would give us the best chance of eliciting a pathogenic polyclonal anti-
MPO response. 
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Light Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Peptide Sequences for amino acids 484-508
Sense:  FRLNNQYRPTAANPRVPLSKVFFAS   
Comp:  AGKKDLAEWDFSGVGRCGPVLIVQAE
Peptide Sequences for amino acids 694-718
Sense:  SNTYPRDFVSCNTLPKLNLTSWKET   
Comp:  GLLPGSQVQFRKGVTADKVSGVCVG
Figure 2.6.  Murine MPO Peptide Sequences Targeted for Sense and 
Complementary Peptide Study.  Shown is an alignment of human and murine MPO 
amino acid sequences, with only the disparate amino acids shown.  All identical amino 
acids appear as dots.  Sense peptides and their complementary counterparts were 
synthesized corresponding to amino acids #484-508 (green box) and #694-718 (red 
box), and the sequences of the sense and complementary (Comp.) pairs are shown.  
Figure adapted from Erdbreugger et al.
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Root-Bernstein and colleagues suggest that complementary proteins play a role in 
autoimmune disease, but their ideas differ slightly from our initial theory.[119] They predict 
that the induction of an autoimmune response comes about when two exogenous antigens 
that share complementary binding regions interact.  At least one of these complementary 
regions is the mimic of a self-antigen.  The complex becomes more immunogenic than either 
antigen individually and induces the simultaneous generation of antibodies specific for each 
complementary site; these antibodies can interact in an anti-idiotpic fashion and create a self-
sustaining network of antibodies which can interact with “self” and incite autoimmunity.  We 
attempted to address Root-Bernstein’s theory by immunizing mice with pre-incubated sense 
and complementary peptide pairs, thus exposing the mice to a complementary peptide 
complex.  We predicted that this complex would be highly immunogenic and incite a more 
potent humoral response, and the mice receiving these splenocytes would have worse 
disease. 
Mice Immunized with m-cMPO peptides did not Produce Anti-MPO Antibodies 
The sera from peptide-immunized mice were analyzed at week 0, 2, and 10 for the 
development of anti-MPO antibodies (Figure 2.7a-d).  It was important that not only the 
complementary peptide-immunized mice develop anti-MPO antibodies to support our theory, 
but also for the sense peptide-immunized mice sera to recognize native MPO; this would 
demonstrate that we chose an appropriate exposed epitope on the surface of the MPO 
molecule.  By ELISA, we showed that the mice responded very well to the peptide 
immunogens both after the first and last immunizations.  However, there was almost no 
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reactivity to native murine MPO, both in the sense and complementary peptide immunized 
mice. 
RAG-2 Knockout Mice that Received Splenocytes from Peptide-immunized Mice did not 
Develop Crescentic, Necrotizing Glomerulonephritis 
 
The positive control RAG-2 -/- mice that received splenocytes from MPO-immunized 
MPO -/- mice were sacrificed at day 12, as they appeared dramatically, physically ill.  
Experimental mice were sacrificed at day 17 when mice from multiple groups began to show 
visible signs of illness.    
Sera from the terminal bleeds of the RAG-2-/- mice were analyzed for the presence of 
anti-MPO antibodies (Figure 2.8).  While it did not appear that the mice had circulating 
antibodies that reacted with the peptides, all mice, including the BSA negative controls, had 
some reactivity to native MPO (Figure 2.8a).  Other than the native MPO-immunized 
splenocyte sera, the m-cMPO peptide- and BSA-immunized splenocyte sera had the highest 
reactivity to native MPO. 
Urine analysis revealed that all mice had some degree of hematuria, the BSA controls 
had the lowest hematuria scores overall (Table 2.1).   However, the scores were inconsistent 
within groups and urine was not collectable from every animal.   
The pathologic evaluation of disease consisted of determining the percent of 
glomeruli with necrosis and crescents within a given microscopic field.  The positive control 
(native MPO-imunized) mice had crescents in 99% of glomeruli and more than 50% of these 
glomeruli were necrotic; this data indicated our model was working well and the anti-MPO 
antibodies induced ANCA disease (Table 2.1).  All mice, including the BSA negative 
controls, had a background mesangial cell proliferation that we commonly see when utilizing  
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Figure 2.7.  Peptide-immunized Mice Sera Reactivity to 
Immunogens and Native Murine MPO.  MPO knockout 
mice were immunized with a) sense peptides (n=5), b) 
complementary peptides (n=5), c) sense-complementary 
peptide complexes (n=5), or d) bovine serum albumin (n=4).  
Sera was acquired  and tested for reactivity against the sense 
peptides (s), complementary peptides (c), native murine MPO 
(mpo) or goat serum blocking buffer (sham) at weeks 0, 2, 
and 13.  e) Serum from a sense peptide (pep)- and a native 
murine MPO (mpo)-immunized mouse was analyzed for 
reactivity to denatured, reduced native MPO by western blot. 
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Figure 2.8.  RAG-2 Knockout Mice Sera Analyzed for Reactivity to 
Immunogens.  Sera from mice acquired on the day of sacrifice was analyzed for 
reactivity by ELISA against a) native murine MPO, b) sense peptides, and c)
complementary peptides.  The mice are grouped according to the splenocytes 
received from the MPO knockouts: either those from mice immunized with sense 
MPO peptides (sense), complementary MPO peptides (comp), sense-complementary 
peptide complexes (complex), bovine serum albumin (BSA), or native murine MPO 
(MPO).  The OD 405 nM value is displayed for each mouse with the mean value for 
each group indicated by the line.   
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Mouse # Splenocytes 
Necrosis 
(%) 
Crescents 
(%) 
Proliferation 
(0-4+) 
Urinalysis* 
(0-3+) 
1 sense 2 3 2 no urine 
2 sense 1 0 2.5 2.5 
3 sense 3 2 2.5 3 
4 sense 1 1 2 1.5 
 
1 complementary 1 0 2 1.5 
2 complementary 0 0 2 3+ 
3 complementary 0 0 1.5 0 
4 complementary 0 0 1.5 1.5 
 
1 complex 2 1 2.5 2 
2 complex 0 0 2 0 
3 complex 0 0 2 3+ 
4 complex 0 1 2 no urine 
 
1 bsa 0 0 2.5 1.5 
2 bsa 1 2 2 0.5 
3 bsa 0 1 2 1.5 
4 bsa 1 0 2 no urine 
 
1 native mpo 55 99 2 no urine 
2 native mpo 65 99 2 no urine 
Table 2.1.  Histopathology and Urinalysis from Splenocyte-transferred RAG-2 -/- Mice 
*Urinalysis for hematuria using Roche Chemstrip 10UA 
89
the splenocyte transfer model.[69] The RAG-2 -/- mice that received splenocytes from MPO    
-/- mice immunized with complementary peptides (alone or complexed weth sense peptides) 
did not develop disease.  The RAG-2 -/- mice that received splenocytes from MPO -/- mice 
immunized with sense peptides developed the most apparent pathologic abnormalities, but 
none of those mice developed more than 3% necrosis or crescents. 
Anti-m-MPO(302-325) Antibodies did not Cross-react with Native Murine MPO 
As the recombinant protein and peptides were not pathogenic, we attempted to map a 
pathogenic region of murine MPO using immunoglobulin from MPO -/- mice immunized 
with purified murine MPO.  The mass spectrometry measurements after the first two 
digestion steps (LysC and trypsin) yielded the same fragment: LysC digestion yielded amino 
acids 219-326, and trypsin revealed a more defined fragment, amino acids 302-325 (Figure 
2.9).  The results after the tryptic digest were confirmed by MS/MS. 
M-MPO(302-325) peptide was ordered from Alpha Diagnostics, Inc., and engineered 
with a N-term cysteine residue for use in linking to carrier proteins or purification columns. 
Prior to receiving the boost at week 4, the m-MPO(302-325) peptide-immunized mice 
did not make anti-peptide antibodies, nor anti-native m-MPO antibodies (not shown).  The 
native m-MPO-immunized mouse generated a potent humoral response to MPO, indicating 
that the adjuvant and procedure were sound.  Analysis of sera at week 1 and 2 following the 
boost revealed that the m-MPO(302-325) peptide-immunized mice made low titer antibodies 
(Figure 2.10).  However, the reactivity of this serum was only 2-fold over the pre-immune 
bleeds and the antibodies did not cross-react with native MPO.  
Because the m-MPO(302-325) peptide was weakly immunogenic and did not incite 
anti-MPO antibody production in the mice, we attempted to use the peptide to compete away 
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binding of MPO-reactive immunoglobulin to MPO as an additional measure of its utility in 
future studies.  Compared to control peptide, MPO(302-325) was unable to compete away 
immunoglobulin binding even in extreme molar excess (Figure 2.11).  The total pooled IgG 
used in this ELISA was the same used to epitope map this peptide, which we expected to 
readily bind the peptide; it does not.  These results provide some uncertainty as to the validity 
of the epitope mapping technique and whether it will be useful in future work.  It must be 
taken into consideration that this mapping was done once and not repeated in this study. 
 
DISCUSSION 
Previously, our group published work supporting autoantigen complementarity as an 
inciting factor in the development of PR3-ANCA-mediated disease.[73] Expanding these 
findings, the work in this chapter demonstrates that MPO-ANCA patients have antibodies 
specific to complementary MPO.  This broadens the application of our Theory of 
Autoantigen Complementarity, which states that the exposure to proteins complementary to 
an autoantigen may elicit an immunologic cascade leading to autoimmunity.  However, it 
remains unproven whether complementary proteins are etiologic agents of disease.  A major 
goal of this research was to induce disease in a mouse model of MPO-ANCA 
glomerulonephritis by immunization with complementary MPO proteins.  
A subset of MPO-ANCA patients had antibodies reactive to recombinant cMPO(420-
697), while healthy controls did not.  These data imply that these patients were exposed to a 
complementary protein, which may have contributed to the onset of disease.  Alternatively, 
the anti-cMPO(420-697) antibodies could be anti-idiotopes generated as an immune 
regulatory response against ANCA.  Because we only have serum from patients after their 
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Figure 2.9.  Epitope Mapping Study Reveals a 24-Amino Acid Epitope.  Shown is 
an alignment of human and murine sequences as described in Figure .  The epitope 
mapping study revealed a peptide epitope corresponding to amino acids 302-325 
(orange box, black arrows), whose sequence is shown above.  For comparison, the 
previously used recombinant protein, m-cMPO(420-697), which corresponds to the 
sense sequence shown by the transparent blue box is shown, along with peptides m-
MPO(484-508) (green box) and m-MPO(694-718) (red box).  
Light Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Heavy Chain
Peptide Sequence for m-MPO(302-325)
CNQINALTSFVDASGVYGSEDPLAR
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Figure 2.10.  m-MPO(302-325) Peptide-immunized Mice do not Have Antibodies 
that Cross-react with Native Murine MPO.  Sera was collected from MPO 
knockout mice that were immunized and boosted with the epitope-mapped, m-
MPO(302-325) peptide (m-MPO(302-325), n=3), native murine MPO (MPO, n=1) 
and adjuvant only (sham, n=2).  Shown is the reactivity from pre-immune sera (W0) 
and sera from weeks 1 (W1) and 2 (W2) following the booster immunization.    
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Figure 2.11.  m-cMPO(302-325) Peptide Does not Compete with Anti-MPO 
Immunoglobulin Binding to Native Murine MPO.  Increasing amounts of the 
epitope-mapped, m-MPO(302-325) peptide were used to compete away the binding 
of two sources of anti-MPO specific immunoglobulin to native MPO.  The “total 
IgG” was the pooled, purified total IgG from three mice that had been immunized 
with native MPO.  This total IgG was that used to epitope map the m-MPO(302-325) 
peptide.  The “serum” was from an MPO knockout mouse that had been immunized 
with native MPO.  The concentrations of the immunoglobulins used were at dilutions 
that represented 50% reactivity to native MPO.  The results are expressed as the 
percent reactivity (as indicated by OD 405 nM by ELISA) of the immunoglobulin in 
the presence of peptide versus that in the absence of peptide. 
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diagnosis as ANCA-positive, we cannot determine the temporal pattern of the appearance of 
the anti-cMPO antibodies versus ANCA and whether the exposure to the complementary 
protein came before, simultaneous to, or after the development of ANCA.  Such studies are 
nearly impossible in humans, which is why an animal model is key to establishing our theory 
as a bona fide mechanism of disease.  One way in which this question may be answered is by 
gaining access to the United States of America Department of Defense serum repository that 
contains 30 million serum samples prospectively collected from more than 5 million service 
men and women.  If some of these people were diagnosed with an ANCA-mediated disease, 
a study could be conducted similar to that published by Arbuckle and colleagues in which 
they analyzed sera for the presence of several autoantibodies associated with systemic lupus 
erythematosis prior to disease diagnosis.[148] For ANCA patients (or other autoimmune 
diseases with defined pathogenic targets), we could determine if the anti-complementary 
protein antibodies were present prior to the development of the autoantibody and onset of 
disease.  
This is not the first report of anti-idiotypic antibodies specific for MPO-ANCA in 
patients.  In a series of studies regarding the mechanism of efficacy of intravenous 
immunoglobulin (IVIg) treatment of ANCA patients, Lockwood and colleagues determined 
that not only the IVIg, but patient sera had anti-MPO anti-idiotopes.[149-152] Their studies 
revealed that Jerne’s Network Theory was potentially at play in regulating the autoimmune 
response as they noted a reciprocal pattern of anti-MPO and anti-idiotypic antibodies over 
time, including a higher titer of anti-idiotopes during disease remission.  They proposed that 
remission of patients was governed by an increase in the anti-idiotopes in circulation.  This 
work was approached from a therapeutic standpoint, and the researchers did not consider that 
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the exposure to a complementary protein could have induced this network and thus disease.  
While not the focus of Lockwood’s research, the identification of these antibodies provides 
further evidence that autoantigen complementarity may be at play is MPO-ANCA vasculitis.      
Establishing an animal model of complementary protein-induced disease without a 
defined pathogenic human MPO epitope proved to be a risky task.  Not only does it appear 
that ANCA are polyclonal among patient populations, none of the multiple reactive regions 
have been finely mapped.  Even if a pathogenic eptitope was known, human ANCA do not 
cause disease in mice, implying that the pathogenic epitope(s) of human MPO contains areas 
of sequence and/or structural divergence from the murine MPO molecule.[144] The lack of 
published data led us to theoretically predict potential pathogenic regions of murine to make 
corresponding complementary recombinant protein and synthetic peptides.  Neither the 
recombinant cMPO(420-697) or the cMPO peptides induced the idiotoypic network in these 
mice, and thus the experiments did not generate ANCA by immunization with a 
complementary peptide.  While the intended use of MPO null mice was to supply a 
permissive environment for the development of anti-idiotopes (anti-MPO), perhaps the use of 
these mice was a disadvantage because these mice had no antigen except for the anti-cMPO 
antibody to drive the production of an MPO cross-reactive antibody.  Based on Root-
Bernstein’s ideas of antigenic complementarity in autoimmune disease, a complex of 
complementary antigens, one of which mimics a self-determinant, is required to induce a 
simultaneous, self-sustaining, and vicious network of autoantibodies and their anti-
idiotopes.[119] In this manner, Jerne’s idiotypic network is not induced in a stepwise fashion.  
Rather, the complementary regions of the antigens generate coincident antibodies that 
interact in an idiotypic fashion.  In our recombinant cMPO experiment, we introduced the 
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complementary protein in the absence of the autoantigen or its mimic, which may have 
shifted the balance of antibody generation in favor of anti-cMPO.  We attempted to address 
this issue by immunizing mice with a complex of complementary synthetic peptides; 
however, the anti-peptide antibodies did not cross-react with native MPO, as discussed 
below.  Additionally, we could not find evidence that recombinant cMPO(420-697) could 
bind MPO (data not shown), which may prove to be a critical element for successfully 
developing a model of our theory. 
A major limitation in using the synthetic peptides was that the antibodies generated 
against the sense peptides did not cross-react with native MPO, confounding the 
establishment of our autoimmune disease model.  Western blots revealed that the anti-sense 
peptide antibodies reacted to reduced, denatured MPO, informing us that the peptides were at 
least proper murine MPO sequences (Figure 2.7d).  Murine MPO has not been crystallized, 
so there was no way to be certain that the selected peptide sequences were exposed on the 
surface of the native molecule.  The shape of these immunogens is of utmost importance.  If 
the sense peptide is not a MPO surface moeity and does not generate antibodies that bind 
native MPO, then it can be inferred that the complementary peptide would not provide the 
predicted internal image of the autoantibody (anti-idiotope).  Thus, the anti-idiotope 
generated following immunization with the complementary peptide would not be expected to 
bind MPO.  
It is interesting that the vast majority of murine studies focused on the idiotypic 
network have utilized the BALB/c strain.[73, 105, 112, 153-155] Our MPO null mice are on 
C57BL/6J background, so there potentially exist genetic differences that more readily permit 
immune “regulation” via the idiotypic network in BALB/c mice compared to C57BL/6J. 
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A promising step forward was the epitope mapping technique that identified a region 
of MPO bound by pathogenic anti-murine MPO immunoglobulin.  A goal of this study was 
to directly identify a peptide that could be used to generate pathogenic antibodies; once 
accomplished, we would create the complementary peptide for use in disease models.  The 
24-amino acid m-MPO(302-325) peptide identified by mass spectrometry was minimally 
immunogenic, generating antibodies at a low titer only after a booster immunization.  This 
region of MPO is highly conserved, not only among muliple species’ myeloperoxidase, but 
also among other murine peroxidases (i.e. thyroid peroxidase, eosinophil peroxidase, and 
lactoperoxidase).  Therefore, naïve B-cell clones that interacted with this peptide were likely 
eliminated in the bone marrow due to the interaction with other self-proteins.  Additionally, 
this peptide shared 92% identity with the homologous human sequence, and structural 
analysis using the National Center for Biotechnology Information’s Cn3d software revealed 
that the majority of this peptide, except for the 4 C-term amino acids, was composed of 
hidden residues.  Regardless, the low titer antibodies failed to cross-react with native MPO.  
The mapping study was only carried out once.  While this attempt did not identify a useful 
epitope, this approach has great potential and repeat studies should be performed.  A 
considerable pitfall with this technique lies in its questionable ability to identify non-linear 
epitopes because, as may be the case with pathogenic murine antibodies, human ANCA seem 
to bind conformational, rather than linear, epitopes.[156] 
In the future, we must learn more about both pathogenic epitope specificities and 
complementary protein interactions to employ a more targeted approach.  As an alternative to 
epitope mapping, we can analyze sequences of known MPO-binding proteins (cytokeratin 1, 
apoA1, ceruloplasmin, and albumin) for regions of predicted hydropathic complementarity 
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and determine if these regions mediate protein-protein interactions.  These may be potential 
regions to target for our studies.  Finding a set of complementary peptides that interact 
specifically with MPO may be key to these studies.  A large scale study involving the 
synthesis of overlapping complementary peptides spanning the entire length of the MPO 
molecule could be employed to screen for peptides that both specificially bind MPO and 
immunoprecipitate anti-idiotypic antibodies from patient/mouse sera.  The strong possibility 
that the pathogenic epitope is conformational complicates matters, as complementary 
peptides based strictly on the linear 5’3’ antisense sequence of MPO may not produce an 
interacting peptide.  While we define a peptide pair based on complementary RNA 
sequences, Bernstein and colleagues define a complementary pair as one in which the 
“antigens must be capable of stereospecific binding to each other that steroespecific binding 
must be manifested by the induction of pairs of complementary antibodies (or T-cells) that 
act like idiotype-antiidiotype pairs.”[119] He provides examples of pairs that fit these criteria 
and cannot be explained by hydropathic complementarity.  This proposal broadens what is a 
complementary peptide.  Because MPO is being studied as a potential drug target to reduce 
oxidative stress in vascular disease, it is possible that companies are conducting high-
throughput studies by screening large peptide libraries for MPO-binding specificity.  A 
collaboration could be established with such companies to acquire sequences of MPO-
binding peptides.  These peptides may represent complementary peptides not able to be 
predicted based on antisense RNA sequence alone, and could be studied by our group to 
discover a complementary peptide that incites disease.   
We have learned in this research that the idiotypic network is intact in ANCA 
patients, which is consistent with the exposure to a complementary protein.  The initial 
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animal experiments revealed regions were not pathogenic, and caused us to use a different 
experimental design.  Before progressing to models of disease, we must determine one or 
more pathogenic epitopes in the mouse model, as well as define a set of complementary 
proteins that can bind MPO.  
EPILOGUE 
 
The inflammatory response is a balance of pro- and anti-inflammatory signals, the 
latter leading to the resolution of inflammation and the repair of host tissue damaged in the 
process.  In some diseases, such as ANCA vasculitis, this delicate balance is shifted toward a 
constant pro-inflammatory state with dramatically disrupted resolution and chronic tissue 
damage.  In these inflammatory conditions, the inhibition of bradykinin production by MPO 
could yield a perpetual impairment of vasodilation by decreasing the bioavailability of nitric 
oxide.  This situation would lead to endothelial dysfunction, a condition underlying diseases 
as diverse as ANCA vasculitis, atherosclerosis, cirrhosis, and diabetes.[157-160] However, one 
must consider whether the detrimental interactions reported in Chapter 1 may also play a 
beneficial role in a controlled inflammatory setting.  The same constraints on bradykinin 
production may contribute to homeostasis, serving to counterbalance the vasodilation and 
edema associated with the initial humoral phase of acute inflammation.  The secondary cell-
mediated phase is characterized by the recruitment of neutrophils and monocytes to the 
inflamed site, upon which MPO is released into the vessel to exert its vasomodulatory 
effects.  In this way, MPO may contribute to host defense while keeping inflammatory 
processes in check.   
Dissection of the molecular mechanisms mediating the inflammatory burden is key to 
revealing targeted, more systemically tolerable, therapeutic targets.  Current therapies used to 
treat ANCA patients are cytotoxic and immunosuppressive:  regimen with serious side 
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effects.  Improving vascular function may be one way in which to alleviate disease symptoms 
and improve outcome in patients.  MPO was previously reported to interfere with nitric oxide 
signaling following its transcytosis through endothelial cells; we provide a new mechanism 
by which MPO prevents nitric oxide production by inhibiting bradykinin release in the 
vessel.  Targeting and inactivating MPO could improve vascular function by protecting the 
activity of the plasma kallikrein-kinin system and the downstream production of nitric oxide.  
However, we must validate the functional relevance of plasma kallikrein-kinin system 
modulation by MPO.  Intricate cell based models need to be established to allow plasma 
kallikrien-kinin system assembly on endothelial cells (in the presence of MPO), as it would 
in the vessel, and monitoring bradykinin production and downstream signaling.  Further, ex 
vivo and/or in vivo physiologic models should monitor the true functional effects of MPO’s 
modulation of bradykinin production. 
Chapter 2 explored the Theory of Autoantigen Complementarity relative to MPO-
ANCA to explain the onset of disease.  Though autoantibodies such as ANCA are recognized 
as pathogenic mediators of disease, the origin of the autoantibodies remains unclear.  We 
found a subset of MPO-ANCA patients that have antibodies reactive to a complementary 
protein, and our theory predicts that these proteins could incite an immunologic cascade 
leading to autoimmunity.  Because proving causation using human material is extremely 
challenging, a major effort was put forth to generate a mouse model of complementary MPO-
induced glomerulonephritis and vasculitis.  However, our attempts were largely unsuccessful.  
Our results indicate that defining a pathogenic region of MPO is paramount before moving 
forward with additional animal studies.  Anti-glomerular basement membrane disease, also 
studied by our group, is mediated by autoantibodies and/or T-cells reactive to a very 
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specified epitope of collagen.  While preliminary, studies in our group have suggested that 
rats immunized with a complementary collagen peptide develop anti-GBM-like disease.  
These studies used a well-defined peptide representative of the GBM epitope that had been 
described years earlier.  We should continue epitope mapping using the mass spectrometry-
based technique described in chapter 2.  While the results of the initial attempt were 
inconclusive, it is a potentially powerful technique that deserves repeating.  Additionally, we 
can epitope map by testing the anti-murine MPO IgG for reactivity against recombinant 
human-mouse MPO chimeras, which are already produced in our laboratory.  This could 
identify a general region of murine MPO for finer mapping studies.  Once we discover a 
pathogenic target sequence, we can design complementary peptides for our studies. 
Scientists have predicted for over 25 years that complementary antigens and the 
idiotypic network could play a role in autoimmune disease.  Proving causation in an animal 
model is currently the “holy grail” that could validate our Theory of Autoantigen 
Complementarity and contribute to a better understanding of one of the mysteries of modern 
medicine: the origin of autoimmune disease.    
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